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BACKGROUND: The angiogenic function of endothelial cells is regulated 
by numerous mechanisms, but the impact of long noncoding RNAs 
(lncRNAs) has hardly been studied. We set out to identify novel and 
functionally important endothelial lncRNAs.
METHODS: Epigenetically controlled lncRNAs in human umbilical 
vein endothelial cells were searched by exon-array analysis after 
knockdown of the histone demethylase JARID1B. Molecular mechanisms 
were investigated by RNA pulldown and immunoprecipitation, mass 
spectrometry, microarray, several knockdown approaches, CRISPR-Cas9, 
assay for transposase-accessible chromatin sequencing, and chromatin 
immunoprecipitation in human umbilical vein endothelial cells. Patient 
samples from lung and tumors were studied for MANTIS expression.
RESULTS: A search for epigenetically controlled endothelial lncRNAs 
yielded lncRNA n342419, here termed MANTIS, as the most strongly 
regulated lncRNA. Controlled by the histone demethylase JARID1B, 
MANTIS was downregulated in patients with idiopathic pulmonary 
arterial hypertension and in rats treated with monocrotaline, whereas 
it was upregulated in carotid arteries of Macaca fascicularis subjected 
to atherosclerosis regression diet, and in endothelial cells isolated 
from human glioblastoma patients. CRISPR/Cas9-mediated deletion or 
silencing of MANTIS with small interfering RNAs or GapmeRs inhibited 
angiogenic sprouting and alignment of endothelial cells in response 
to shear stress. Mechanistically, the nuclear-localized MANTIS lncRNA 
interacted with BRG1, the catalytic subunit of the switch/sucrose 
nonfermentable chromatin-remodeling complex. This interaction was 
required for nucleosome remodeling by keeping the ATPase function of 
BRG1 active. Thereby, the transcription of key endothelial genes such as 
SOX18, SMAD6, and COUP-TFII was regulated by ensuring efficient RNA 
polymerase II machinery binding.
CONCLUSION: MANTIS is a differentially regulated novel lncRNA 
facilitating endothelial angiogenic function.
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The endothelium forms the central vascular barrier to maintain vessel function and integrity. Healthy endothelium prevents thrombus formation, leu-
kocyte adhesion, and smooth muscle cell proliferation, 
whereas activated endothelium has opposing proper-
ties.1 Understanding how endothelial cells maintain or 
change their phenotype is key to preventing vascular 
disease development. Important aspects in this regula-
tion are epigenetic mechanisms, but our understanding 
of vascular epigenetics is still in its beginning.
Epigenetic mechanisms regulating gene expression 
involve chromatin modifications without associated 
DNA sequence alterations. For example, trimethylation 
at histone 3 lysine 4 (H3K4) in promoter regions is gen-
erally associated with gene expression.2,3 The H3K4 ly-
sine-specific demethylase 5B (JARID1B) has been shown 
to maintain normal endothelial gene expression by lim-
iting expression of gene repressors.4 Several chromatin-
modifying complexes have been found to be important 
for endothelial gene expression. In human umbilical 
vein endothelial cells (HUVECs), for example, polycomb 
repressor complex-2 (PRC2) regulates gene expression 
of Ten-eleven translocation-1.5 Moreover, the catalytic 
subunit of the switch/sucrose nonfermentable (SWI/
SNF) complex, Brahma related gene-1 (BRG1), is recruit-
ed to the endothelial nitric oxide synthase promoter un-
der hypoxic conditions,6 and to the Selectin E promoter 
under resting conditions.7 Knockout of BRG1 or loss of 
PRC2 function results in mouse embryonic lethality,8,9 
highlighting the importance of epigenetic modifiers for 
vascular development. Moreover, BRG1 has been iden-
tified as a central regulator of gene expression, eg, of 
Chicken Ovalbumin Upstream Promoter Transcription-
Factor-2 (COUP-TFII) in vascular cells.10
Epigenetic functions are also mediated by RNAs. 
Only a small portion of the human genome carries 
protein-coding potential; the majority is differentially 
and dynamically transcribed to produce noncoding 
RNAs, of which the majority are long noncoding RNAs 
(lncRNAs).11 LncRNA is the most diverse, plastic, and 
poorly understood class of noncoding RNA. It is broadly 
defined as transcribed, but not translated, RNA mol-
ecules >200 nucleotides in length.12 Many lncRNAs are 
associated with epigenetic factors, where they recruit 
chromatin-modifying complexes, such as PRC2, to tar-
get sites. Through this and other mechanisms, lncRNAs 
influence transcriptional activation or repression, de-
pending on the interaction partner.11 So far, only a few 
lncRNAs have been shown to contribute to vascular 
disease and endothelial cell integrity.13 This contrasts 
with the important role of the endothelium in vascu-
lar biology. In the present study, we set out to identify 
epigenetically controlled endothelial lncRNAs possess-
ing relevant and novel functions. Among them, we fo-
cused on the unreported lncRNA n342419, which we 
named MANTIS, and establish this as a disease-relevant 
element controlling vascular transcription factor expres-
sion through BRG1.
METHODS
All methods are described in detail in the online-only Data 
Supplement.
Primers
The primers for quantitative real-time polymerase chain reac-
tion are listed in online-only Data Supplement Table I. The 
primers for chromatin immunoprecipitation are listed in 
online-only Data Supplement Table II.
Statistics
Unless otherwise indicated, data are given as means±standard 
error of mean. Calculations were performed with Prism 5.0 
or BiAS.10.12. The latter was also used to test for normal 
distribution and similarity of variance. In case of multiple test-
ing, Bonferroni correction was applied. For multiple group 
comparisons, analysis of variance followed by post hoc test-
ing was performed. Individual statistics of dependent sam-
ples were performed by paired t test, of unpaired samples 
by unpaired t test, and, if not normally distributed, by Mann-
Whitney test. P values of <0.05 were considered as signifi-
cant. Unless otherwise indicated, n indicates the number of 
individual experiments.
Study Approval
The study protocol for tissue donation from patients who have 
human idiopathic pulmonary hypertension was approved by 
the ethics committee (Ethik Kommission am Fachbereich 
Clinical Perspective
What Is New?
• MANTIS is a long noncoding RNA strongly regu-
lated by histone demethylase JARID1B.
• MANTIS maintains endothelial cell function.
• It interacts with the nucleosome-remodeling pro-
tein BRG1.
• It maintains ATPase activity of BRG1 by stabilizing 
the switch/sucrose nonfermentable complex.
• MANTIS promotes transcription of SOX18, SMAD6, 
and COUP-TFII by enabling RNA polymerase II bind-
ing to the transcriptional start sites.
• MANTIS is downregulated during pulmonary arterial 
hypertension but induced in tumor endothelium.
What Are the Clinical Implications?
• MANTIS is a novel long noncoding RNA that posi-
tively affects endothelial angiogenic function. 
• Altering MANTIS expression could be exploited 
to control the angiogenic process in situations of 
excessive or insufficient angiogenesis.
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Humanmedizin der Justus Liebig Universität Giessen) of the 
University Hospital Giessen (Giessen, Germany) in accordance 
with national law and with Good Clinical Practice/International 
Conference on Harmonisation guidelines. Written informed 
consent was obtained from each individual patient or the 
patient’s next of kin (AZ 31/93, 10/06, 58/15).14
Studies for human glioblastoma were covered by an eth-
ics statement according to the guidelines of the University 
of Frankfurt, whose approval number for autopsy material is 
GS-249/11 and for resection material, GS-04/09.
Animal experiments regarding severe combined immu-
nodeficiency mice were performed in accordance with 
the National Institutes of Health Guidelines on the Use of 
Laboratory Animals. The University Animal Care Committee 
and the Federal Authorities for Animal Research (Darmstadt, 
Germany) approved the study protocol.
Animal studies regarding rats were performed accord-
ing to the guidelines of the University of Giessen and were 
approved by the local authorities (GI 20/10 Nr.44/2013).
Experiments on adult male cynomolgus monkeys were 
approved by the Institutional Care and Use Committee of the 
University of Iowa as approved experiments in this study.15
RESULTS
MANTIS Is a JARID1B-Suppressed lncRNA 
Downregulated in Human Idiopathic 
Pulmonary Arterial Hypertension
To identify epigenetically controlled lncRNAs, the impact 
of the knockdown of the histone demethylase JARID1B 
on endothelial RNA expression was determined by Exon 
arrays. JARID1B is one of the highest expressed histone 
demethylases in HUVECs.4 The expression of several ln-
cRNAs was altered by depletion of JARID1B with small 
interfering RNAs (siRNAs) (Figure 1A, online-only Data 
Supplement Table III, online-only Data Supplement Fig-
ure IA), of which n342419 and n406914 were most 
consistently regulated (online-only Data Supplement 
Figure IB). Expression of n342419 was much higher 
than that of n406914 in HUVECs (online-only Data 
Supplement Figure IC), and the RNA was also most 
strongly induced by JARID1B knockdown (online-only 
Data Supplement Figure IB) and dependent on histone 
modification changes rather than direct transcriptional 
repression (online-only Data Supplement Figure ID).
On the basis of these features, we decided to fur-
ther focus on this uncharacterized lncRNA, which is 
genomically located as intronic antisense to Annexin 
A4 (ANXA4) (online-only Data Supplement Figure 
IE). Given the multiple cryptic names of n342419, ie, 
ANXA4-AS, uc002sft.1, and AK125871, we decided 
to name this lncRNA MANTIS based on its secondary 
structure. No indication of peptide-coding potential 
was found with open reading frame (ORF) determi-
nation by the RiboTaper16 method and by the coding 
potential assessment tool17 (online-only Data Supple-
ment Figure IF and IG). In contrast to the positive 
control DYR, artificial in vitro translation suggested 
that MANTIS does not encode a protein with a mo-
lecular weight >10 000 Dalton (online-only Data Sup-
plement Figure IH). None of the in silico predicted 
ORFs within the MANTIS sequence were identified in 
searches of a HEK Proteome with the PRIDE database 
(PXD000705, online-only Data Supplement Tables IV 
and V). A search for micropeptides after overexpres-
sion of MANTIS in HUVECs with subsequent liquid 
chromatography-tandem mass spectrometry without 
trypsination showed that none of the micropeptides 
found had any similarity to potential MANTIS ORFs, 
whereas the positive control yielded micropeptides 
encoded from GFP plasmid (online-only Data Supple-
ment Tables VI and VII). A second experiment using 
MANTIS overexpressing HUVECs, this time with tryp-
sination before liquid chromatography-tandem mass 
spectrometry, revealed no micropeptides with similar-
ity to potential MANTIS ORFs, suggesting that MANTIS 
is noncoding (online-only Data Supplement Tables VIII 
and IX), thereby also minimizing the lack of detection 
by mass spectrometry, which does not exclude the 
presence of micropeptides. The expression of MANTIS 
was not restricted to HUVECs and even not to endo-
thelial cells; MANTIS could also be detected in aortic, 
lymphatic, and pulmonary artery endothelial cells, in 
human smooth muscle cells isolated from different ar-
teries, fibroblasts, MCF-7 cells, and THP-1 monocytes 
(online-only Data Supplement Figure II).
It is important to note that the expression of MAN-
TIS was also altered in the disease context. In lungs 
from patients with end-stage idiopathic pulmonary 
arterial hypertension (IPAH), an isolated small-vessel 
disease accompanied by endothelial dysfunction, en-
dothelial apoptosis, and proliferation,18 MANTIS was 
downregulated, whereas JARID1B was upregulated 
(Figure 1B). A similar regulation pattern was also 
found in pulmonary artery endothelial cells (online-on-
ly data Supplement Figure IIA). Conversely, during vas-
cular regeneration, JARID1B was downregulated and 
MANTIS was induced, as observed in the atheroscle-
rosis regression phase in samples obtained from a M. 
fascicularis high-fat feeding study15 (Figure 1C). In en-
dothelial cells isolated from glioblastoma or adjacent 
healthy brain tissue, MANTIS was increased, whereas 
JARID1B was decreased (Figure 1D), which was also 
shown for MANTIS by RNA in situ hybridization using 
RNAscope (Figure 1E). Similarly, laminar flow induced 
MANTIS, whereas it decreased JARID1B expression 
(Figure 1F). To identify a functional role of MANTIS, 
loss-of-function approaches were used in the cell cul-
ture system with HUVECs. Because full-length MANTIS 
is only partially conserved beyond primates, studying 
its physiological importance by genetic knockout in 
mice is difficult. Therefore, we determined the capac-
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Figure 1. Endothelial angiogenic capacity is dependent on lncRNA MANTIS. 
A, Affymetrix Exon-array heatmap comparing siJARID1B-1/siScr, siJARID1B-2/siScr, siJARID1B-1/siGFP, siJARID1B-2/siGFP, and siScr/
siGFP levels of HUVEC batches 1 to 3. Scale bar shows color code from –2.7 (blue) to 2.4 (yellow) log2 fold change. lncRNAs 
marked by an asterisk revealed >1 noncode accession numbers. See online-only Data Supplement Table III and online-only Data 
Supplement Figure IA for all lncRNA names. B, qRT-PCR of MANTIS and JARID1B in lungs from control donors (CTL) or patients 
with IPAH. n=12. Median with interquartile range is shown, and Mann-Whitney test was used. C, qRT-PCR of MANTIS and 
JARID1B in monkey vessels treated either with a normal diet (CTL), a high-fat diet (Ath), or a high-fat diet and a subsequent 
recovery phase (Reg). n=3. One-way ANOVA, Bonferroni. D, qRT-PCR of MANTIS and JARID1B from endothelial cells isolated from 
glioblastoma (GBM) or adjacent healthy control (CTL) tissue. n=5. Paired t test. E, RNA in situ hybridization of endothelium of 
healthy brain or glioblastoma with RNAscope. Scale bar indicates 50 µm. Arrows point to dots indicating MANTIS RNA. F, qRT-PCR 
measurements relative to β-Actin of MANTIS and JARID1B after laminar flow exposure (shr, 20 dyn/cm2) for 48 hours or 72 hours 
in HUVECs as indicated. Static (stc) samples served as control. n=4. Unpaired t test. G, CRISPR/Cas9 MANTIS guide RNAs (MTS 
gRNA) and control cells (CTL) after in vivo matrigel angiogenesis assay in mice. HUVECs were embedded in matrigel, stained with 
Vybrant dil (red), and injected. Isolectin GS-IB4 Alexa 647 conjugated stained vessels (green). Images were taken by light sheet mi-
croscopy 26 days after injection. Representative pictures are shown. Scale bar indicates 200 µm. H, Quantification of cells per plug 
as shown in G 26 days after injection. n=3. Unpaired t test. I, Tube formation assay performed with MTS gRNA and CTL. Numbers 
indicate number of tubes ± SEM. n=3. Scale bar indicates 200 µm. J, Spheroid outgrowth assay with MANTIS (Continued )  
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ity of HUVECs with or without CRISPR/Cas9-mediat-
ed deletion of MANTIS to integrate into the vascular 
network of matrigels injected in severe combined im-
munodeficiency mice. Importantly, deletion of MAN-
TIS resulted in a >50% reduction of the capacity of 
HUVEC to be retained in this model (Figure 1G and 
1H, online-only Data Supplement Figure IIB and IIC). 
In addition, CRISPR/Cas9-mediated knockout of MAN-
TIS in HUVECs greatly attenuated tube formation and 
sprouting (Figure 1I and 1J).
Because genetic deletion of MANTIS greatly re-
duced cellular health, siRNAs were used as a less 
drastic knockdown strategy. Of the 3 different siRNAs 
used, all reduced MANTIS expression, albeit siRNA-1 
being most effective (online-only Data Supplement 
Figure IID). Therefore, siRNA-1 was used for the sub-
sequent experiments. MANTIS siRNA-mediated deple-
tion reduced endothelial sprouting (Figure 1K and 1L, 
online-only Data Supplement Figure IIE and IIF) and 
tube formation (Figure  1M), also in pulmonary ar-
tery endothelial cells (online-only Data Supplement 
Figure IIG). Moreover, it attenuated migration of HU-
VECs in Boyden-Chamber assays (online-only Data 
Supplement Figure IIH). In a competition-like spher-
oid outgrowth assay, siMANTIS-transfected cells were 
underrepresented in the tip cell position (online-only 
Data Supplement Figure III and IIJ). Also, the ability 
of HUVECs to properly orientate toward the direction 
of flow was lost after the knockdown of the lncRNA 
(Figure 1N).
The regulation of MANTIS by JARID1B was further 
studied by chromatin immunoprecipitation experi-
ments. JARID1B bound H3K4me3-rich regions near 
the transcriptional start site (TSS) of MANTIS (online-
only Data Supplement Figure IIK). Knockdown of JA-
RID1B increased H3K4me3 close to the TSS of MAN-
TIS (online-only Data Supplement Figure IIL), whereas 
other family members such as JARID1A and JARID1C 
did not regulate MANTIS (online-only Data Supple-
ment Figure IIM).
Together, these data suggest that the lncRNA MAN-
TIS could be of importance during IPAH and glioblasto-
ma and that its control by Jarid1B is essential to preserve 
multiple aspects of normal endothelial cell functions in 
culture and in a mouse in vivo model.
MANTIS Interacts With the SWI/SNF 
Chromatin-Remodeling Complex Subunit 
BRG1
To get insights into the molecular mechanism by which 
MANTIS controls endothelial cell functions, we first evalu-
ated the intracellular localization of MANTIS in HUVECs. 
RNA-fluorescence in situ hybridization demonstrated that 
the endogenous MANTIS RNA is localized in the nucleus, 
whereas the negative control ACTINB mRNA was pre-
dominantly localized in the cytosol. Also, after overex-
pression, MANTIS was retained in the nucleus (Figure 2A).
To identify candidates as interaction partners of MAN-
TIS, RNA-pulldown experiments with 3ʹ-biotinylated 
MANTIS lncRNA or 3ʹ-biotinylated pcDNA3.1+ negative 
control RNA with nuclear extracts from HUVECs were 
performed (Figure 2B). As expected, MANTIS was strong-
ly enriched in the 3ʹ-biotinylated MANTIS pulldowns in 
comparison with the controls (Figure 2C). Electrospray 
ionization mass spectrometry of the samples identified 
several coprecipitating proteins as candidates for interac-
tion (Figure 2D and 2E, online-only Data Supplement Ta-
ble X), with BRG1 having the highest score. The ATPase 
BRG1 is a known regulator of endothelial cell functions 
and has been shown to be increased in humans with 
thoracic aortic aneurysms and to impact on prolifera-
tion, apoptosis, and myocardin-specific gene regulation 
in vascular smooth muscle cells.19,20 Importantly, reverse 
RNA immunoprecipitation and RNA chromatin immu-
noprecipitation all confirmed MANTIS as an interaction 
partner of BRG1. The interaction of MANTIS with BRG1 
was specific: MANTIS was not pulled down by SMAR-
CA5, the catalytic subunit of the ISWI chromatin-remod-
eling complex,21 or IgG (Figure 2F and 2G). BRG1 also 
did not coprecipitate with MEG3 lncRNA or U12 snRNA. 
These data show that MANTIS and the SWI/SNF catalytic 
subunit BRG1 are interacting. Potentially, this interaction 
mediates the physiological effects of MANTIS.
MANTIS Is Required for the Gene 
Expression of SOX18, SMAD6, and COUP-
TFII
A key function of lncRNAs associated with chromatin-
remodeling complexes is the regulation of transcriptional 
Figure 1 Continued. gRNA and CTL. Cells treated with or without VEGF-A are shown. Scale bar indicates 50 µm. K, Spheroid 
outgrowth assay after siMTS. Scr served as negative control. Cells treated ± VEGF-A are shown. Scale bar indicates 50 µm. L, 
Quantification of sprout numbers from the spheroid outgrowth assays seen in K or online-only Data Supplement Figure IIE. n=10. 
One-way ANOVA, Bonferroni. M, Tube formation assay after siMTS. Scr served as negative control. Numbers indicate number 
of tubes ± SEM. n=3. Scale bar indicates 200 µm. N, Images of cells treated with scrambled or siMTS after 72 h of laminar flow 
(LSS, 20 dyn/cm2). Numbers indicate number of cells orientated in direction of the flow ± SEM. n=4. Scale bar indicates 100 µm. 
All qRT-PCR data are relative to β-actin. Error bars are defined as mean ±SEM. *P<0.05. ANOVA indicates analysis of variance; 
HUVEC, human umbilical vein endothelial cell; IPAH, idiopathic pulmonary arterial hypertension; lncRNA, long noncoding RNA; 
qRT-PCR, quantitative real-time polymerase chain reaction; Scr, scrambled; SEM, standard error of the mean; siMTS, MANTIS 
siRNA; and VEGF-A, vascular endothelial growth factor A.
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Figure 2. The nuclear localized MANTIS lncRNA interacts with the SWI/SNF complex member BRG1. 
A, RNA fluorescence in situ hybridization (FISH) of HUVECs with TYE-665–modified probes against ACTINB and MANTIS. 
DAPI was used to stain nuclei. MANTIS overexpression (OE) samples were treated with an additional overexpression of 
pcDNA3.1+MANTIS for 48 hours before FISH. Scale bar indicates 20 µm. B, Scheme of RNA pulldown assay with subsequent 
preparation for mass spectrometric measurements. b-RNA indicates biotinylated RNA. C, qRT-PCR after RNA pulldown assay 
by measuring the amount of MANTIS RNA (MTS) in the eluates relative to the negative control RNA (CTL). n=4. Paired t test. 
D, Volcano plot of log2 ratio of MANTIS versus control interaction partner proteins after RNA pulldown assay and ESI-MS/MS 
measurements. n=3. Noncorrected –log10 Student t test. LFQ indicates label-free quantification. E, Proteins (Continued )  
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events.22 Thus, microarrays were used to identify the 
impact of MANTIS knockdown on endothelial gene ex-
pression. Depletion of MANTIS with LNA-GapmeRs led 
to downregulation of a high number of angiogenesis-re-
lated mRNAs, among them SRY (Sex Determining Region 
Y)-Box 18 (SOX18), Mothers against decapentaplegic ho-
mologue 6 (SMAD6), and COUP-TFII, and on upregulation 
of stress-induced genes like interleukin 6 and superoxide 
dismutase 2 (Figure  3A, online-only Data Supplement 
Table XI); however, genes neighboring the MANTIS locus 
in the genome (ANXA4, AAK1, GCML1, snRNP27) were 
not affected, excluding a cis-regulatory activity of MAN-
TIS in HUVEC (Figure 3B). To confirm these results, quanti-
tative real-time polymerase chain reaction after depletion 
of MANTIS with either LNA-GapmeRs, siRNAs, or CRISPR/
Cas9 deletion mutants was performed. All silencing ap-
proaches confirmed the data obtained with the micro-
arrays (Figure 3C and 3D, online-only Data Supplement 
Figure IIIA through IIIF). Gene ontology (GO) analyses 
for genes downregulated in response to MANTIS knock-
down yielded angiogenesis as the most significantly af-
fected GO term (Figure 3E, online-only Data Supplement 
Tables XII and XIII). Indeed, it has been reported previously 
that SOX18, SMAD6, and COUP-TFII are key endothelial 
genes important for angiogenesis and other endothelial 
features mentioned in reference 23.
On this basis, mRNA data were validated on the pro-
tein level. Western blot analyses revealed that both, 
LNA-GapmeRs and siRNAs, as well, not only reduced 
MANTIS mRNA, but also SOX18, SMAD6, and COUP-
TFII protein levels in HUVECs (Figure 3F through 3I). Giv-
en the potential function of SOX18 for lymphatic and 
of COUP-TFII for venous specification, additional cell 
types were studied. Downregulating MANTIS, however, 
yielded similar responses in human dermal lymphatic 
endothelial cells, aortic arterial and pulmonary artery 
endothelial cells, and even vascular smooth muscle cells 
(online-only Data Supplement Figure IIIG through IIIL).
The fact that SOX18, SMAD6, and COUP-TFII were 
also downregulated in the samples of patients with 
IPAH in which also MANTIS was downregulated, might 
suggest that this interaction also occurs in the disease 
context (Figure 3J through 3L), because, in endothelial 
cells isolated from glioblastoma, SOX18, SMAD6, and 
COUP-TFII were increased (online-only Data Supple-
ment Figure IIIM through IIIO).
To establish a link between these MANTIS target 
genes and endothelial angiogenic capacity, siRNA-based 
knockdown was performed (Figure 4A). Downregula-
tion of either of SMAD6, COUP-TFII or SOX18 all attenu-
ated endothelial sprouting in the spheroid outgrowth 
assay (Figure 4B through 4D). However, overexpression 
of SMAD6, COUP-TFII, or SOX18 after MANTIS knock-
down (online-only Data Supplement Figure IVA and 
IVB) failed to normalize endothelial sprouting capacity 
(online-only Data Supplement Figure IVC and IVD). This 
might suggest that several factors acting in concert are 
affected by MANTIS or that technical difficulties arising 
from multiple transfections and from the great size of the 
MANTIS plasmid render these studies infeasible. To ad-
dress the second aspect, we searched for a fragment of 
MANTIS with RegRNA2.0,24 which might be sufficient to 
rescue endothelial function after MANTIS knockdown. 
A small part of ≈450 nt of MANTIS Exon 3 contains an 
Alu element, which could be of functional importance 
(online-only Data Supplement Figure IE). Overexpression 
of this element (MANTIS-mut) indeed partially rescued 
the sprouting in response to vascular endothelial growth 
factor A (Figure 4E through 4H). Thus, MANTIS main-
tains endothelial angiogenic capacity through an induc-
tion of SMAD6, COUP-TFII, and SOX18, and this effect 
is potentially mediated by the Alu element in Exon 3. In-
terestingly, a corresponding SINE B1 (short interspersed 
nucleotide element) was also found in mice and rats at 
a similar position within the Intron of ANXA4. In CD31+ 
positive cells isolated from rats exposed to monocrota-
line, a model system frequently used to study pulmo-
nary arterial hypertension,25 expression of this putative 
homologue MANTIS fragment was downregulated, ten-
dentially together with SOX18, SMAD6, and COUP-TFII 
(Figure 4I). This might suggest that this lncRNA is con-
served from humans to rats and that the Alu element is 
important in regulating IPAH.
MANTIS and BRG1 Facilitate RNA 
Polymerase II Binding by Reducing 
Heterochromatin
BRG1 functions as an ATP-dependent helicase in the 
SWI/SNF chromatin-remodeling complex.26 Interesting-
ly, it has been shown that BRG1 promotes COUP-TFII 
gene expression in vascular endothelium during mu-
Figure 2 Continued. enriched after RNA pulldown assay, their score, ratio MANTIS/CONTROL (MTS/CTL), and t value. F, MANTIS 
lncRNA (Left), U12 snRNA (Middle), and MEG3 lncRNA (Right) binding to complexes RNA immunoprecipitated with IgG, anti-
BRG1, anti-SMARCA5, and anti-H3 were measured with qRT-PCR. The binding was analyzed relative to the input. Log2 values are 
shown. n=6. One-way ANOVA, Bonferroni. G, MANTIS lncRNA (Left), U12 snRNA (Middle), and MEG3 lncRNA (Right) binding to 
complexes RNA-chromatin immunoprecipitated with IgG, anti-BRG1, anti-SMARCA5, and anti-H3 were measured with qRT-PCR. 
The binding was analyzed relative to the input. Log10 values are shown. n=6. One-way ANOVA, Bonferroni. Error bars are defined 
as mean ± SEM. *P<0.05. ANOVA indicates analysis of variance; DAPI, 4ʹ,6-diamidino-2-phenylindole; ESI-MS/MS, electrospray 
ionization-tandem mass spectrometry; HUVEC, human umbilical vein endothelial cell; lncRNA, long noncoding RNA; qRT-PCR, 
quantitative real-time polymerase chain reaction; SEM, standard error of the mean; and SWI/SNF, switch/sucrose nonfermentable.
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Figure 3. LncRNA MANTIS is required for SMAD6, COUP-TFII, and SOX18 expression. 
A, Illumina Bead-Chip Array heat map comparing gene expression after MANTIS LNA-GapmeR versus Control LNA-GapmeR 
treatments for 48 hours. Scale bar shows color code from –2.8 (green) to 2.4 (red) log2 fold change. Only representative 
genes were shown. B, qRT-PCR after LNA-GapmeR knockdown of MANTIS lncRNA. Expression levels of MANTIS, ANXA4, 
GCML1, snRNP27, and AAK1 are shown. CTL LNA served as negative control and was set to 1. n=4, Paired t test. C, qRT-PCR 
after LNA-GapmeR based knockdown of MANTIS lncRNA. CTL served as negative control and was set to 1. Expression levels 
of MANTIS, SOX18, SMAD6, COUP-TFII, and SOD2 are shown. n=6. Paired t test. D, qRT-PCR after knockdown of MANTIS 
lncRNA with siRNA-1. Scrambled siRNA (Scr) and MANTIS siRNA-specific control siRNA (CTL) served as negative controls. Ex-
pression levels of MANTIS, SOX18, SMAD6, COUP-TFII, and SOD2 are shown. Scr was set to 1. n=7. One-way ANOVA, Bonfer-
roni. E, Gene ontology (GO) analyses made with Gorilla using all significantly downregulated genes after MANTIS knockdown 
found in the array. F, Representative Western blot of HUVECs treated either with control or MANTIS LNA-GapmeRs. SMAD6, 
SOX18, and COUP-TFII antibodies were used. GAPDH served as control. G, Quantification of blots shown in F. CTL was set 
to 1. n=3, Paired t test. H, Representative Western blot of HUVECs treated either with control or MANTIS siRNA-1. SMAD6, 
SOX18, COUP-TFII, and ANXA4 antibodies were used. GAPDH served as control. I, Quantification of blots shown (Continued )  
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rine embryonic development by customizing its pro-
moter for the transcriptional machinery.10 To address 
the question whether MANTIS contributes to BRG1 nu-
cleosome-remodeling activity, an Assay for Transposase 
Accessible Chromatin with subsequent DNA Sequenc-
ing (ATAC-Seq) was performed. The protein level of 
BRG1 was not changed by MANTIS depletion (Figure 
5A). ATAC-Seq analysis after MANTIS knockdown re-
vealed less open chromatin at the transcriptional start 
sites (TSS) of SMAD6, SOX18, and COUP-TFII, whereas 
the MANTIS TSS served as control (Figure 5B, online-
only data Supplement Figure VA, online-only data Sup-
plement Table XIV). The decrease in open chromatin at 
the TSS of SMAD6, SOX18, and COUP-TFII could be de-
tected by Formaldehyde-Assisted Isolation of Regulato-
ry Elements (FAIRE) (Figure 5C), which is an alternative 
to DNase I.27 To characterize the nucleosome occupan-
cy, micrococcal nuclease (MNase) digestion was per-
formed. MNase cuts preferentially linker DNA, whereas 
the nucleosomal DNA is partially protected because it is 
insensitive for MNase digestion.27 As expected, MNase 
digestion resulted in increased nucleosome formation 
at the TSS of SMAD6, SOX18, and COUP-TFII (Figure 
5D). Because BRG1 is involved in nucleosome remodel-
ing, MANTIS may impact the compaction of chromatin 
and thus provides access of RNA polymerase II to the 
DNA. To demonstrate this, chromatin immunoprecipi-
tation experiments of H3K27me3, heterochromatin 
protein 1α (HP1α), histone 3 (H3), and histone 4 (H4) 
were performed. On the GAPDH promoter no differ-
ence was observed, whereas on SOX18 TSS, SMAD6 
TSS, and COUP-TFII TSS, H3K27me3 binding was in-
creased by depletion of MANTIS (Figure 5E). For SOX18 
and SMAD6 TSS, an additional increase of H3, H4, and 
HP1α binding was observed, which was only partially 
seen for COUP-TFII (online-only data Supplement Fig-
ure VB through VD). Consequently, MANTIS depletion 
decreased RNA polymerase II binding near the TSS 
of SMAD6, SOX18, and COUP-TFII, but not near the 
GAPDH TSS or further upstream of the promoters of 
SMAD6, SOX18, and COUP-TFII (Figure 5F). Impor-
tantly, and causative for the previous results, depletion 
of MANTIS resulted in a decreased binding of BRG1 
near the TSS of SMAD6, SOX18, and COUP-TFII (Figure 
5G), substantiating the concept that the nucleosome-
remodeling activity of BRG1 on the SMAD6, COUP-TFII, 
and SOX18 TSS is dependent on MANTIS, which may 
assist proper chromatin decompaction and thus may 
prepare the promoters for the recruitment of the RNA 
polymerase II transcriptional machinery.
By Stabilizing the Interaction Between 
BRG1 and BAF155, MANTIS Is Required 
for the ATPase Function of SWI/SNF
It is thought that the remodeling activity of BRG1 is 
stimulated by BAF155.28 To understand the functional 
role of MANTIS within the SWI/SNF complex, the inter-
actions of BRG1 with its interaction partners BAF155 
and BAF53A were studied by proximity ligation assays 
(Figure 6A). The binding of BRG1 to BAF155 was sig-
nificantly reduced by depletion of MANTIS (Figure 6B), 
whereas the interaction for BAF53A was not changed 
and LIS1 served as negative control. Vice versa, overex-
pression of MANTIS or the MANTIS Alu element mutant, 
but not C- or N-terminal MANTIS deletion mutants, was 
sufficient to increase the interaction between BRG1 
and BAF155 in the proximity ligation assay (Figure 6C 
and 6D). Importantly, the reduced interaction of BRG1 
to BAF155 after knockdown of MANTIS was not a con-
sequence of decreased BAF155 or BRG1 protein expres-
sion as determined by Western blot analysis (Figure 6E). 
Given that MANTIS depletion decreased the interaction 
of BRG1 with BAF155 and also decreased the ability of 
BRG1 to bind on its target gene promoters, we mea-
sured the ATPase activity of BRG1 after the protein 
was immunoprecipitated from cells with and without 
MANTIS depletion. Importantly, BRG1 ATPase activity 
was drastically decreased by MANTIS knockdown (Fig-
ure 6F). These findings indicate that MANTIS improves 
the ATPase activity of BRG1 by stabilizing its interaction 
with BAF155.
DISCUSSION
In the present study, we identified the epigenetically 
regulated and previously unstudied lncRNA MANTIS 
(n342419) to be upregulated by knockdown of JA-
RID1B and in vascular pathologies, whereas in IPAH 
MANTIS was repressed. Depletion of MANTIS reduced 
the endothelial angiogenic function ex vivo and in vivo. 
Mechanistically, MANTIS acts in trans through the SWI/
SNF chromatin-remodeling factor BRG1 for which it fa-
cilitates the interaction with angiogenic genes and with 
the BRG1 stimulating factor BAF155. Thus, with the 
present work, we establish a putative link of a lncRNA 
acting through a novel mechanism of transacting ln-
cRNAs in essential epigenetic regulatory mechanisms in 
endothelial cells, which is misregulated in patients with 
IPAH and glioblastoma (Figure 7). In contrast to cis-act-
ing lncRNAs, which are often found to act on neigh-
Figure 3 Continued. in H. Scr was set to 1. n=4. Paired t test. J through L, qRT-PCR of SMAD6 (J), COUP-TFII (K), and SOX18 
(L) in lungs from control donors (CTL) or patients with IPAH. n=12. Unpaired t test. All qRT-PCRs are relative to ß-Actin. Error 
bars are defined as mean ± SEM. *P<0.05. CTL indicates control; HUVEC, human umbilical vein endothelial cell; IPAH, idio-
pathic pulmonary arterial hypertension; lncRNA, long noncoding RNA; MTS, MANTIS; qRT-PCR, quantitative real-time poly-
merase chain reaction; Scr, scrambled; SEM, standard error of the mean; and SOD2, superoxide dismutase 2.
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Figure 4. SMAD6, SOX18, or COUP-TFII knockdown resemble MANTIS-deficient phenotype. 
A, qRT-PCR measurements after siRNA-based knockdown for 48 hours of MANTIS lncRNA (MTS), SMAD6, COUP-TFII, or 
SOX18. Scrambled siRNA (Scr) served as negative control and was set to 1. Expression levels of MANTIS (MTS), SMAD6, COUP-
TFII, and SOX18 relative to β-ACTIN are shown. n=9. Paired t test. B, Spheroid outgrowth assay after MANTIS, SMAD6, COUP-
TFII, or SOX18 siRNA-based knockdown for 48 hours. Scrambled siRNA (Scr) served as negative control. Cells treated with or 
without VEGF-A (±VEGF-A) are shown. Scale bar indicates 50 µm. C, D, Quantifications of sprout numbers (C) and cumulative 
sprout length (D) from the spheroid outgrowth assays shown in B. n=4. One-way ANOVA, Bonferroni. E, qRT-PCR measure-
ments of MANTIS-mutant (MTS-mut) after overexpression (OE) of HUVEC with CTL or MTS-mut. n=6. Paired t test. F, Spheroid 
outgrowth assay after Scrambled (Scr) or MANTIS siRNA knockdown (siMTS) with subsequent overexpression of either CTL or 
MTS-mut for 24 hours. Cells treated with or without VEGF-A (±VEGF-A) are shown. Scale bar indicates 50 µm. G, H, Quantifi-
cation of sprout numbers (G) and cumulative sprout length (H) from the spheroid outgrowth assays shown in F. n=5. One-way 
ANOVA, Bonferroni. I, qRT-PCR of MANTIS, SOX18, SMAD6, and COUP-TFII in PECAM-positive lung endothelial cells isolated 
from rats treated with saline (CTL) or monocrotaline (MCT). n=3. rn indicates rattus norvegicus. Unpaired t test. Error bars 
are defined as mean ± SEM. *P<0.05. ANOVA indicates analysis of variance; HUVEC, human umbilical vein endothelial cell; 
PECAM, platelet endothelial cell adhesion molecule; qRT-PCR, quantitative real-time polymerase chain reaction; SEM, standard 
error of the mean; and VEGF-A, vascular endothelial growth factor A.
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Figure 5. MANTIS facilitates nucleosome remodeling by BRG1. 
A, Representative Western blot of HUVECs treated either with scrambled (Scr) or with MANTIS siRNA-1 (MTS) for 48 hours. 
GAPDH served as loading control. B, ATAC-Seq profiles of genomic loci of SOX18, SMAD6, COUP-TFII, and ANXA4 after trans-
fection of HUVECs with scrambled (CTL) or MANTIS siRNA (siMTS) underlined with Refseq and University of California, Santa 
Cruz annotation. For all, number of reads ranges from 0 to 13. r indicates reads; and a, alignment. Arrows indicate regions 
of strong differences between CTL and siMTS. C, D, qPCR of indicated genomic loci relative to GAPDH after transfection of 
HUVEC with scrambled (CTL) or MANTIS siRNA (siMTS) with subsequent FAIRE (C) or Mnase (D). Numbers indicate nucleotide 
positions upstream of the TSS. CTL was set to 1. n=4, paired t test. E through G, ChIP of HUVECs transfected with scrambled 
(C) or MANTIS siRNA (M) with H3K27me3 (E, n=6), RNA Pol II (F, n=3), and BRG1 (G, n=4) followed by qPCR for GAPDH pro-
moter, Sox18 promoter regions at the transcription start site (TSS, –39 nt) or 586 nt and 1022 nt, SMAD6 promoter regions at 
the transcription start site (TSS, –29 nt) or 1491 nt and 3031 nt, and COUP-TFII promoter regions at the transcription start site 
(TSS, –137 nt) or 534 nt and 3185 nt. Numbers indicate nucleotide positions upstream of the TSS. Unpaired t test. Error bars 
are defined as mean ± SEM. *P<0.05. ChIP indicates chromatin immunoprecipitation; FAIRE, Formaldehyde-Assisted Isolation 
of Regulatory Elements; HUVEC, human umbilical vein endothelial cell; MNase, micrococcal nuclease; nt, nucleotide; qPCR, 
quantitative polymerase chain reaction; RNA Pol II, RNA polymerase II; SEM, standard error of the mean; and TSS, transcrip-
tional start site.
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boring gene expression by influencing RNA stability or 
local epigenetic processes, transacting lncRNAs typically 
function in miRNA sponging or regulating epigenetics 
in the form of scaffolding epigenetic complexes.11,29 
The involvement of the transacting lncRNA MANTIS in 
ATPase activity modulation therefore represents a novel 
and essential epigenetic regulatory mechanism in en-
dothelial cells.
Expression of Brg1 in Tie2+ cells is critical for mouse 
embryonic development as yolk sac–derived blood cells 
from Brg1fl/fl:Tie2-Cre+/0 embryos underwent apopto-
sis at embryonic day 9.5.30 Moreover, after knockout, 
the yolk sac vessels exhibited failure to interconnect, 
which lead to dead-end vascular termini reflecting that 
sprouting or pruning progression failed. This supports 
the potential in vivo function of the proangiogenic ln-
cRNA MANTIS. The endothelial BRG1 knockout vascu-
lar morphology could be rescued by LiCl treatment,31 
highlighting, on the one hand, the stabilization of the 
Wnt signaling molecule β-catenin, but, on the other 
hand, the importance of RNA.32 Also the BAF155 ho-
mologue Srg3−/−Tg+ mouse embryo yolk sacs showed 
poorly developed vasculatures accompanied by reduced 
expression of many angiogenesis-related genes.33 This 
strengthens our hypothesis that the BRG1-BAF155 axis 
is required for angiogenesis-related gene expression. In 
this axis, our data suggest that MANTIS supports this 
interaction. We furthermore identified MANTIS lncRNA 
as dependent on the histone demethylase JARID1B. 
JARID1B, which is known to have a great overlap on 
target genes with polycomb proteins in embryonic stem 
cells, has been shown to function in the control of de-
velopmental processes like retina and eye development, 
neural differentiation, and respiratory failure.4,34 Devel-
A
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Figure 6. MANTIS improves ATPase activity of BRG1 by stabilizing its interaction with BAF155.  
A, Proximity ligation assay (PLA) of HUVECs transfected with scrambled (Scr) or MANTIS siRNA-1 (siMTS) for BRG1 with 
BAF155, BAF53a, or LIS1. LIS1 served as negative control. Red dots indicate polymerase-amplified interaction signals. Scale bar 
indicates 20 µm. B, Quantifications of PLA shown in A. n=3, Unpaired t test. Maxima indicate number of dots originating from 
polymerase-amplified interaction signal. C, Scheme of different MANTIS mutants used in D. Numbers indicate Exon number; 
A, Alu element. D, Relative increase of BRG1/BAF155 interaction from a PLA after overexpression of MANTIS mutants. n=6, 
Unpaired t test. E, Representative Western blot of HUVECs treated either with scrambled (Scr) or with MANTIS siRNA-1 (MTS) 
for 48 hours for BRG1, BAF155, and BAF53a. F, ATPase activity assay (absorbance at 620 nm) after BRG1 immunoprecipitation 
of HUVECs transfected with scrambled (Scr) or MANTIS siRNA-1 (MTS) for 48 hours. n=5, Paired t test. Error bars are defined 
as mean ± SEM. *P<0.05. HUVEC indicates human umbilical vein endothelial cell.
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opmental importance was also shown for the knockout 
mice of the PRC2 components Suz129 and the endo-
thelium-specific deletion of Jarid2, which led to cardiac 
defects.35 MANTIS could serve here as a stimulus of 
BRG1 function to compensate the loss of JARID1B.
We identify the endothelial genes SOX18, SMAD6, 
and COUP-TFII as targets of MANTIS. These genes are 
known to be important in angiogenesis,23,36,37 eg, (1) 
SOX18 induced adipose-derived stromal cells with an 
endothelial phenotype involved in vascular pattern-
ing,36 (2) SMAD6 gene knockout led to cardiovascular 
defects,38 and (3) deletion of COUP-TFII was embryoni-
cally lethal and caused impaired angiogenesis, abnor-
mal heart development, and aberrant formations of the 
vasculature.39 We explored how MANTIS collectively 
regulated these angiogenesis-related genes. BRG1 is 
known to be a critical regulator of COUP-TFII expression 
in the cardiovascular system.10,20 Our data confirm this 
finding, but also demonstrate that BRG1 acts on SOX18 
and SMAD6. MANTIS directly interacts with BRG1, and 
increases its ATPase activity by promoting BAF155 in-
teraction. Genome-wide effects could be identified by 
endothelial ATAC-Seq. Thus, MANTIS appears to keep 
the SWI/SNF complex intact and preserve the catalytic 
activity of BRG1. Indeed, loss of BRG1 binding on tar-
get gene promoters consistently correlated with a de-
crease of mRNA expression of these target genes af-
ter MANTIS knockdown. Even in the rat MCT model, 
where the putative homologous MANTIS in the form 
of its regulatory SINE B1 was reduced, the expression 
of these target genes tended to be reduced. Together 
with endothelial-specific deletion of BRG1 leading to 
amelioration of pulmonary hypertension,40 this finding 
suggests a critical role of the MANTIS-BRG1 axis in en-
dothelial dysfunction, and offers a potential therapeutic 
option for pulmonary hypertension and glioblastoma. 
In case of pulmonary hypertension, several structural 
changes in the pulmonary arteries (loss of the distal 
pulmonary vasculature (vascular pruning), development 
of neointima and plexiform lesions, and remodeling of 
the distal pulmonary arteries contribute to the develop-
ment and progression. Moreover, Masri et al41 demon-
strated that cells from the IPAH patients are impaired in 
their ability to form tube-like structures in culture, and 
this may be responsible for their inability to reconstitute 
the lost distal pulmonary vascular bed. This phenotype 
copies the results of MANTIS knockdown in endothelial 
cells. Quite the opposite situation is present in glioblas-
toma. In the endothelium of these tumors, expression 
of MANTIS is high, and a highly angiogenic situation is 
present in glioblastoma. Vessels show defective endo-
thelium and abnormal morphology by, eg, dilatation, 
disorganization, and high permeability, which is a con-
sequence of high levels of vascular endothelial growth 
factor A.42,43 On this basis, it is attractive to speculate 
that MANTIS could be exploited to alter angiogenesis 
in patients.
Upregulation of MANTIS in Macaca aortae in the 
regression phase after atherosclerotic diet could imply 
an involvement of this lncRNA in vascular regeneration. 
Because MANTIS depletion affected several angiogen-
esis-relevant genes, it is unclear whether other target 
genes from the microarray experiment are directly de-
pendent on MANTIS and the SWI/SNF complex.
Figure 7. Model of mechanism of action for the lncRNA MANTIS.  
Upper, MANTIS lncRNA expression is controlled by the histone demethylase JARID1B. Because of the limited expression of 
MANTIS, BRG1 and BAF155 assembly is decreased, leading to more heterochromatin formation at the TSS of SOX18, SMAD6, 
and COUP-TFII, limiting RNA Pol II binding and transcription of those genes. Lower, In case of JARID1B knockdown, H3K4me3 
levels arise at the TSS of MANTIS, allowing more MANTIS expression. MANTIS interacts with BRG1, allowing increased binding 
of BAF155, which leads to a higher ATPase activity of BRG1 and euchromatin formation at the TSS of SOX18, SMAD6, and 
COUP-TFII allowing RNA Pol II binding and thereby transcription of SOX18, SMAD6, and COUP-TFII, which leads to increased 
angiogenic function. lncRNA indicates long noncoding RNA; RNA Pol II, RNA polymerase II; and TSS, transcriptional start site.
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The interaction between BRG1 and BAF155 has been 
demonstrated to increase ATPase activity of BRG1.28 
BAF155, however, was not identified as an interaction 
partner of MANTIS. Therefore, we speculate that MAN-
TIS enhances the affinity of BRG1 to bind to BAF155 
through binding to another so-far-unknown BAF155 
recruiting factor. Such a protein could be GPATCH4, 
whose G-Patch domain is known to mediate RNA-pro-
tein interactions. Another possibility involves structural 
changes of BRG1 after MANTIS binding to enhance 
BAF155 binding affinity or to allow amino acid modifi-
cations. These could in turn enhance BRG1s affinity to 
bind to BAF155, possibly by the action of the MANTIS 
Alu element. In respect to BRG1 ATPase function, it has 
been reported that the lncRNA EVF2 directly inhibits the 
ATPase and chromatin-remodeling activity of BRG1.44 
A similar inhibiting function on BRG1 could be found 
for the lncRNA Myheart (Mhrt). Mhrt was identified to 
inhibit myopathy and chromatin remodelers.45 In ven-
tricles of mouse hearts, Mhrt interacts with the helicase 
domain of BRG1, thereby repressing chromatin target 
recognition of BRG1. It is notable that BRG1 itself re-
presses the expression of Mhrt. Although EVF2 and Mhrt 
were predominantly studied in mice, and assuming that 
their function is conserved and that gene expression of 
them is given to a certain extent in the individual cells, 
they could represent counterparts to the BRG1 promot-
ing lncRNA MANTIS. However, one can speculate that 
the SWI/SNF complex assembly is different from cell type 
to cell type. The current report of a facilitation of ATPase 
function is, however, novel. MANTIS appears to mediate 
this effect through a scaffolding function in SWI/SNF.
Taken together, these findings suggest that MANTIS 
lncRNA plays a significant and unique role for endothe-
lial cell function by acting as a scaffolding lncRNA with-
in a chromatin-remodeling complex, mediating and di-
recting efficient key endothelial gene transcription.
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Supplemental Methods Materials.  
Human recombinant VEGF-A 165 was purchased from R&D (293-VE) and human recombinant TNF-α 
was from Peprotech (300-01A). The following antibodies were used: Anti-COUP-TFII (TA324540, 
Origene), Anti-GAPDH (PA1-16777, Thermo Fisher), Anti-BRG1 (A300-813A, Bethyl), Anti-BAF155 
(A301-021A, Bethyl), Anti-JARID1B (A301-813A, Bethyl), Anti-BAF53a (A301-391A, Bethyl), Anti-
BAF60a (A301-595A, Bethyl), Anti-LIS1 (A300-409A, Bethyl), Anti-H3K27me3 (pAb-069-050, 
Diagenode), Anti-HP1α (A300-877A, Bethyl), Anti-ANXA4 (R2053-1, Abiocode), Anti-SMARCA5 
(SNF2h/ISWI, Bethyl, A301-017A-T), Anti-SOX18 (H-140, Santa Cruz), Anti-SMAD6 (ab13727, Abcam). 
Anti-beta-ACTIN (4970, Cell Signaling), Anti-H3-pan (C15310135, Diagenode), Anti-H4-pan 
(C15410156, Diagenode), Anti-PolII (C15100055, Diagenode).  Human lung samples and patient characteristics. 
Human explanted lung tissues from subjects with IPAH or control donors were obtained during lung 
transplantation. Samples of donor lung tissue were taken from the lung that was not transplanted. 
All lungs were reviewed for pathology and the IPAH lungs were classified as grade III or IV.  Experimental mice and light sheet microscopy.  
All experimental procedures were approved by the local governmental authorities and were 
performed in accordance with the local animal protection guidelines. CRISPR/Cas9 HUVEC and 
control HUVEC were stained with Vybrant Dil Cell-Labeling solution (V-22885, Thermo Fisher) and 
embedded as spheroids into matrigel and injected into SCID-Mice similar as described previously by 
others1. After 26 days, Isolectin GS-IB4 from Griffonia simplicifolia, Alexa Fluor® 647 Conjugate 
(I32450, Thermo Fisher) was injected via the tail vein and was allowed to circulate for at least 10 min. 
Afterwards, animals were killed and perfused transcardially. The plugs were dissected and fixed in 4% 
Paraformaldehyde (PFA) overnight and subsequently cleared following the 3DISCO procedure2. 
Imaging was carried out with the Ultramicroscope II (UM-II, LaVision Biotec, Bielefeld) at 20x 
magnification (10 Zoom body + 2x Objective). Pictures were taken with Neo 5.5 (3-tap) sCOMs 
Camera (Andor, Mod.No.: DC-152q-C00-FI). The ImSpectorPro Version 5.0.110 was used. 3D Images 
and quantification were performed with Imaris (Bitplane Version 7.6). Auto fluorescence signals were 
deleted manually with the surface function. Background subtraction was done with the background 
subtraction algorithm (filter width = 2000µm). Cells were detected and counted with the Spots-
Algorithm (Estimated Diameter = 10.0 µm; Background Subtraction = true; Intensity Center Ch=3" 
above 720; Region Growing Type = Local Contrast). Lower threshold was chosen depending to the 
background signal. Experimental monkeys. 
Macacae fasciculari vessels were kindly provided by one of the co-authors (FJM) and originated from 
3. Cynomolgus monkeys were fed either with a normal diet, an atherosclerotic diet for 47±10 (mean ± 
SE) months, or an atherosclerotic diet with an additional recovery/regression phase for 8 months. 
500ng of RNA was reverse transcribed and expression levels of GAPDH, JARID1B and MANTIS were 
measured with qRT-PCR with Macacae fascicularis specific primers. Relative expression of target 
genes was normalized to GAPDH and analyzed by the delta-delta Ct method with the MxPro qPCR 
software (Stratagene). 
 
 
Experimental rats, MCT treatment and isolation of lung vascular endothelial cells. 
Rat studies were performed according to the guidelines of the University of Giessen and were 
approved by the local authorities (GI 20/10 Nr.44/2013). Adult male Sprague-Dawley rats (300-350 g 
body weight (BW)) were given a subcutaneous injection of saline (healthy control, n=3) or 
monocrotaline (MCT; 60 mg/kg BW, n=3) as described4. The BW changes and survival were 
monitored from 1 to 35 days for all groups.  
After euthanasia by removing blood, rat lung vascular endothelial cells were isolated after 
explantation of the lung. The lung tissue was separated from heart, trachea and oesophagus, cut into 
small slices (1mm) and washed in Hank’s balanced salt solution (HBSS, without CaCl2, MgCl2) to 
remove remaining blood. Minced tissues were transferred in sterile tubes containing 40ml HBSS 
(with CaCl2 and MgCl2), 5U/ml Dispase and 20mg Dnase. Tissue was digested for 90min in a water 
bath with gentle shaking at 37°C. By using continuous pipetting, cells were released from the lung 
tissue and the residual tissue was removed by filtering the suspension through 70μm mesh filter into 
a tube with Medium 199 (Gibco) containing 10% FCS. The cell suspension was centrifuged at 290g for 
5min at room temperature (RT). After centrifugation the cell pellet was washed with 5ml HBSS 
containing 0,5% BSA. The cells were resuspended in 800μl HBSS containing 0.5% BSA. For binding the 
mouse anti-rat CD31 (550300, BD Pharmingen) antibody to the Dynabeads M-450 Tosylactivated 
(14013, Invitrogen), 40μl Dynabeads were coated with 8μl of the antibody. Then the cell suspension 
was incubated with the antibody coupled beads in an end-over-end shaker at RT for 90min. The 
unbound cells were removed by washing 3 to 5 times with HBSS containing 0.5% BSA using a 
magnetic device (Dynal MPC-1, Invitrogen). Brain microvessel isolation from glioblastoma (GBM) patients. 
Fresh brain specimens were obtained from GBM patients within 3h post surgery. For patients, where 
the normal appearing healthy tissue was not available, healthy material was obtained from epilepsy 
or dementia patients or autopsy material within a day postmortem. An ethics statement covered all 
studies on these subjects. The ethics approval number for autopsy material is GS-249/11 and for 
resection material GS-04/09. Human brain microvessels (HBMV) were isolated as described 
previously with a few modifications5. Briefly, the specimen obtained in ice-cold microvessel buffer 
(MVB, 15mM HEPES, 147mM NaCl, 4mM KCl, 3mM CaCl2, 1.2mM MgCl2, 5mM glucose and 0.5% BSA, 
pH 7.4) was cleared of blood and any meningeal tissue using forceps. The tissue was homogenized in 
3-fold ice-cold MVB buffer by 15 up and down strokes in a tight-fitting douncer (0.25 mm clearance, 
10ml Wheaton) attached to an electrical overhead stirrer (2000 rpm, VOS 14, VWR). After 
centrifugation of the homogenate (400xg, 10 min, 4°C), the pellet was resuspended in 4-fold 25% 
BSA (in PBS) followed by centrifugation (2000xg, 30 min, 4°C). Myelin fat appearing in the top 
buoyant layer after the centrifugation was aspirated. The pellet was resuspended in 3ml ice-cold 
MVB (per gram) of the starting material. The resuspended microvessels were filtered through 100-
micron sterile nylon mesh cell strainer (BD) to remove large vessels and tissue aggregates. The 
filtrate was further applied to 40-micron sterile nylon mesh (BD) to trap the microvessels and to 
remove platelets, cell debris and nuclei as filtrate. After washing the mesh once with ice-cold MVB, 
microvessels were lysed directly on the mesh with ice-cold RLT-Plus RNA lysis buffer (Qiagen). The 
samples were vortexed for 1 min and stored at -80°C until use.  
 
 
Cell culture.  
Pooled human umbilical vein endothelial cells (HUVECs) were purchased from Lonza (CC-2519, Lot 
No. 371074, 369146, 314457, 192485, 186864, 171772, Walkersville, MD, USA) and PELOBiotech (PB-
CH-190-813, Lot No. QC-18P13F11, Planegg, Germany). Human aortic endothelial cells (HAoEC) were 
purchased from PeloBiotech (304K-05a). Human pulmonary artery endothelial cells (PAEC) were 
obtained from Promocell (C-12241, Heidelberg, Germany). HUVECs, HAoECs and PAECs were 
cultivated in a humidified atmosphere of 5% CO2 at 37°C. To culture the cells, Fibronectin-coated 
(356009, Corning Incorporated, USA) dishes were used. Endothelial growth medium (EGM), 
consisting of endothelial basal medium (EBM) supplemented with human recombinant epidermal 
growth factor (EGF), EndoCGS-Heparin (PeloBiotech, Germany), 8% fetal calf serum (FCS) (S0113, 
Biochrom, Germany), penicillin (50 U/ml) and streptomycin (50 µg/ml) (15140-122, Gibco/ 
Lifetechnologies, USA) was used. For HAoEC, 16% FCS was used instead of 8%. For each experiment, 
at least three different batches of HUVEC from passage 3 were used.  
Human aortic smooth muscle cells (HAoSMC, 354-05a), human coronary artery smooth muscle cells 
(CASMC, 350-05a) and human carotid artery smooth muscle cells (CTASMC, 3514-05a) were 
purchased from PeloBiotech (Planegg, Germany) and cultured in a humidified atmosphere of 5% CO2 
at 37°C in smooth muscle cell medium (PB-MH-200-2190) supplemented with 8% FCS, penicillin 
(50 U/ml), streptomycin (50 µg/ml), EGF, fibroblast growth factor, glutamine, and insulin from 
singlequots (PeloBiotech, Planegg, Germany). 
Human dermal lymphatic endothelial cells (HDLEC, #3111203.4, #394Z027.3, #4092401.3) were 
purchased from Promocell (Heidelberg, Germany) and cultured in a humidified atmosphere of 5% 
CO2 at 37°C in endothelial cell growth medium MV2 (Promocell, Heidelberg, Germany).  
Human foreskin fibroblasts, obtained from Gibco (Lifetechnologies, Carlsbad, CA, USA), were cultured 
in DMEM/F12 (#11039-021) supplemented with 10% FCS, penicillin (50 U/ml), and streptomycin (50 
μg/ml) in a humidified atmosphere of 5% CO2 at 37°C. 
The human monocytic cell line THP-1 and cancer cell line MCF-7, obtained from ATCC (LGC 
Promochem, Wesel, Germany), were cultured in RPMI medium containing stable glutamine, 8% FCS 
and 1% penicillin/streptomycin (PAA Laboratories, Cölbe, Germany) in a humidified atmosphere of 
5% CO2 at 37°C. Knockdown and overexpression procedures.  
For small interfering RNA (siRNA) treatments, endothelial cells (80–90% confluent) were transfected 
with GeneTrans II according to the instructions provided by MoBiTec (Göttingen, Germany). All 
siRNAs (Stealth RNAi) were from Invitrogen. MANTIS and MANTIS-Control (C) siRNAs were designed 
with the BLOCK-iT RNAi designer (Invitrogen). The siRNAs had the following sequences: MANTIS-1: 5’-
AAA UGA AGC AGC CUU GUU GUC UGG G, MANTIS-1-C: AAA UCU GAA GCG ACG UUC UGU UGG G, 
MANTIS-2: AAC AGA AGA AGA UCC AGC AGU UAU A, MANTIS-3: UUU GAU GGA ACC UUG UUC CAU 
GAG G. As negative control, scrambled Stealth RNAi™ Med GC (Life technologies) was used. Other 
siRNAs used targeted JARID1B (stealth siRNA, HSS173871, Invitrogen), SMAD6 (stealth siRNA, 
HSS106261, Invitrogen), COUP-TFII (stealth siRNA, HSS110656, Invitrogen) and SOX18 (Silencer 
select, s195242, #4392420, Invitrogen). The siRNA knockdown started for rescue experiments 24h 
prior to overexpression and did not exceed 48h in total. For shear stress experiments, 24h prior to 
 
 
the application of the laminar flow the transfection was performed. All other siRNA experiments 
were performed for 48h. Small hairpin RNA (shRNA) treatments were performed exactly as described 
in6. For Locked nucleic acid (LNA)-GapmeR (Exiqon) treatment, the transfection was performed with 
the Lipofectamine RNAiMAX (Invitrogen) transfection reagent according to manufacturer’s protocol. 
All LNA-GapmeR transfections were performed for 48h. The LNA-GapmeRs were designed with the 
Exiqon LNA probe designer and contained the following sequences: For MANTIS 5’-ACA TAG ATG GAC 
TCT T-3’ and as negative Control 5’-AAC ACG TCT ATA CGC-3’.  
Plasmid overexpression in HUVECs was performed with the Neon electroporation system (Invitrogen) 
with the following plasmids: pCMV-SOX18 (SC113502, Origene), pCMV-SMAD6 (SC320357, Origene), 
pCMV-COUP-TFII (SC108069, Origene) and pcDNA3.1+MANTIS-mutant (MTS-mut). 
PcDNA3.1+MANTIS was obtained from Biomatik (Canada). PcDNA3.1+MANTISΔC, 
pcDNA3.1+MANTISΔN1 and pcDNA3.1MANTISΔN2 were generated as described. As a negative 
control, empty pcDNA3.1+ was used. Plasmid transfection for Spheroid sprouting assay was 
performed for 48h. RNAscope 
RNA in situ hybridization was performed with the RNAscope 2.5 HD Detection reagent (322310, 
Advanced Cell Diagnostics (ACD), Newark, CA, USA) as a single-plex chromogenic brown assay 
according to manufacturer’s instructions with minor changes. Briefly, formalin fixed paraffin-
embedded sections were deparaffinized and treated with hydrogen peroxide for 10min. Afterwards, 
target retrieval was carried out using the Braun steamer. The sections were incubated in boiling 1 x 
Retrieval solution for 20min. Then they were incubated with protease Plus for 30min at 40°C using 
the HybEZ System. The probe (MANTIS (Hs-AK12587) (ACD #483551)) and amplification steps were 
carried out according to instructions except that Amp5 was incubated for 60min. To detect the 
signal, sections were incubated with DAB for 20min at RT. Finally sections were counterstained with 
10% Gill’s Hematoxylin No. 1 for 20sec and blued in tap water. After dehydration sections were 
mounted using EcoMount and analyzed by light microscopy. Affymetrix Exon-Array and Illumina BeadChip Array. 
For Exon-Array experiments, HUVECs were transfected with control (Scrambled Stealth RNAi™ Med 
GC, 12935-300, Invitrogen) or JARID1B stealth siRNAs (HSS173871, Invitrogen). 48h after 
transfection, RNA was isolated with the miRNeasy Mini Kit (Qiagen) and a GeneChip Human Exon 1.0 
ST array (Affymetrix) was used. Data was analyzed by using the noncoder web interface 7 and the 
Robust Multichip Average normalization method.  
For Illumina Array experiments, HUVECs were transfected with control or MANTIS LNA-GapmeRs 
(Exiqon) for 48h and RNA was isolated subsequently with the miRNeasy Mini Kit (Qiagen). 
Afterwards, the Illumina HumanHT12-v4 Expression BeadChip Array was performed (ServiceXS). Raw 
data was used to generate a data intensity table by extracting all average microarray signals per gene 
symbol and sample. Next, a log2 data transformation was used to variance-stabilize the signals and 
the robust spline normalization8 implemented in the lumi package9 was used to normalize variance-
stabilized data. For detection of differentially expressed genes, limma10 was used to fit a linear model 
for each gene and a series of normalized array data. We next calculated moderated t-statistics, F-
statistics and log-odds of differential expression by empirical Bayes moderation of the standard 
 
 
errors towards a common value10 and calculated the adjusted p-value according to Benjamini-
Hochberg. 
Gene Ontology terms were searched by using the web-interface of Gorilla with standard parameters 
(http://cbl-gorilla.cs.technion.ac.il/)11, where the p-value is the enrichment p-value computed 
according to the mHG (minimal hypergeometric) or HG model. RNA isolation, Reverse transcription and quantitative real-time PCR (qRT-PCR).  
Total RNA Isolation was performed with the RNA Mini Kit (Bio&Sell). Reverse transcription was done 
with SuperScript III Reverse Transcriptase (Thermo Fisher) and oligo(dT)23 together with random 
hexamer primers (Sigma). CopyDNA amplification was measured with qRT-PCR using Eva Green 
Master Mix and ROX as reference dye (Bio&Sell) in a Mx3000P cycler (Stratagene). Relative 
expression of target genes was normalized to ß-Actin or 18S ribosomal RNA and analyzed by the 
delta-delta Ct method with the MxPro qPCR software (Stratagene). Protein Isolation and Western Analyses.  
Cells were washed 2 times in Hanks solution (Applichem) and lysed with Triton X-100 lysis buffer 
(20 mM Tris/Cl pH 7.5, 150 mM NaCl, 10 mM NaPPi, 20 mM NaF, 1% Triton, 2 mM Orthovanadat 
(OV), 10 nM Okadaic Acid, protein-inhibitor mix (PIM), 40 µg/ml Phenylmethylsulfonylfluorid 
(PMSF)). Afterwards, cells were centrifuged for 10 min at 16,000 g. Protein concentration was 
determined with the Bradford assay. Afterwards, cell extract was boiled in Laemmli buffer, equal 
amounts of protein were separated with SDS-PAGE and gels were blotted onto a nitrocellulose 
membrane. After blocking in Rotiblock (Carl Roth, Germany), first antibody was applied. Infrared-
fluorescent-dye-conjugated secondary antibodies were purchased from Licor (Bad Homburg, 
Germany). Signals were detected with an infrared-based laser scanning detection system (Odyssey 
Classic, Licor, Bad Homburg, Germany). CRISPR/Cas9.  
Guide RNA (gRNA) development was based on the web-interfaces of CRISPR design 
(http://crispr.mit.edu/) or CHOPCHOP (https://chopchop.rc.fas.harvard.edu/). The pSpCas9(BB)-2A-
Puro (PX459) V2.0 was a gift from Feng Zhang (Addgene plasmid # 62988) and used as cloning 
backbone. The CRISPR/Cas9 procedure in HUVEC was carried out after12. Briefly, two PX459 V2.0 
plasmids containing gRNA sequences for targeting the MANTIS gene at the 5’site and at the 3’site 
were used in combination for transfection. The following oligonucleotides were used for annealing: 
For pSpCas9(BB)-2A-Puro-5’Exon1-MANTIS 5’-CAC CGC TTC ATT TTG AGG GCT CGT C-3’ and 5’-AAA 
CGA CGA GCC CTC AAA ATG AAG C-3’ and for pSpCas9(BB)-2A-Puro-3’Exon4-MANTIS 5’-CAC CGC TAC 
CAC TTG GCA ACC CGC T-3’ and 5’-AAA CAG CGG GTT GCC AAG TGG TAG C-3’. After cloning, plasmids 
were purified and sequenced. The transfection of a GFP control plasmid (pcDNA3.1-GFP) or the 
pSpCas9(BB)-2A-Puro-5’Exon1-MANTIS and pSpCas9(BB)-2A-Puro-3’Exon4-MANTIS constructs into 
HUVEC was achieved using the NEON electroporation system (Invitrogen), afterwards puromycin 
(1µg/mL) was used as selection reagent for 5 days. Shear stress exposure.  
Untreated or 24h siRNA-treated 2x105 HUVECs were plated overnight on fibronectin coated µ-slides I 
0.4 Luer (Ibidi) and cultured in a humidified atmosphere of 5% CO2 at 37°C in EGM. The next day, 
medium was replaced by new EGM and the cells were exposed to laminar flow (20 dynes/cm2) under 
 
 
the control of the Ibidi perfusion system for 72h to mimic shear stress. In parallel, the static control 
samples were treated identically except that these were not exposed to shear stress. Afterwards, 
images were taken with an Axiovert135 (Zeiss) microscope. HUVECs under static conditions without 
laminar flow served as negative control.  Matrigel assay (Tube formation).  
Matrigel Growth Factor Reduced (BD) was prepared and incubated with 1x105 HUVECs in EBM and 
1%FCS for 4h similar to 13. After stopping with 4% PFA, tube formation images were acquired on an 
Axiovert135 microscope (Zeiss). Tube number quantification was analyzed with the help of 
AxioVision software (Zeiss). Spheroid outgrowth assay.  
HUVEC spheroids were generated as described in 14. Images were acquired with an Axiovert135 
microscope (Zeiss). For quantification of the cumulative sprout number, ten spheroids per condition 
were analyzed with the help of the AxioVision software (Zeiss). Treatments with VEGF-A 165 were 
performed for 16h with a concentration of 10ng/mL. 
For the competition-like spheroid outgrowth assay, spheroids of HUVEC were made from two 
differently treated groups. For this, HUVEC were transduced with lentivirus to express Yellow 
Fluorescent Protein (YFP) and Cyan Fluorescent Protein (CFP), respectively. The cell population 
expressing CFP was used as control cells transfected with scrambled siRNA, whereas the other 
expressing YFP was transfected with MANTIS siRNA. Both cell populations were mixed (1:1) and the 
spheroid assay was performed as described above. Images were taken with the laser scanning 
microscope LSM 510 META (Zeiss) and processed with ZEN 2011 software (Zeiss). Boyden-chamber assay. 
Boyden-chamber assays were performed similar to15. For the boyden-chamber assay, 200,000 HUVEC 
were plated on membrane inserts (FluoroBlok, 3μm pore size, BD Bioscience, Heidelberg, Germany) 
in the presence of EBM, whereas the lower chamber contained EBM supplemented with 4% FCS. 
HUVEC on the upper surface of the filter were removed mechanically after 20h. Then, HUVEC in the 
lower chamber were fixed (4% paraformaldehyde in PBS), stained with DAPI and counted. In vitro transcription and RNA 3’end biotinylation.  
Prior to in vitro transcription, pcDNA3.1+MANTIS or control pcDNA3.1+ were linearized with SmaI 
(Thermo Fisher). After precipitation and purification of linearized DNA, DNA was in vitro transcribed 
according to the manufacturers protocol with T7 Phage RNA Polymerase (NEB), and DNA was 
digested with RQ DNase I (Promega). The remaining RNA was purified with the RNeasy Mini Kit 
(Qiagen) and biotinylated at the 3’end with the Pierce RNA 3’end biotinylation kit (Thermo Fisher).  RNA pulldown assay and peptide purification for mass spectrometry.  
The RNA pulldown assay was performed similar to 16. For proper RNA secondary structure formation, 
150ng of 3’end biotinylated MANTIS RNA or control RNA was heated for 2 min at 90°C in RNA folding 
buffer (10 mM Tris pH 7.0, 0.1 M KCl, 10 mM MgCl2), and then put on RT for 20 min. 1x107 HUVECs 
were used per sample. Isolation of nuclei was performed with the truCHIP™ Chromatin Shearing Kit 
(Covaris, USA) according to the manufacturers protocol without shearing the samples. Formaldehyde 
samples were crosslinked prior to cell harvest and quenched. Folded Bait RNA was incubated in 
 
 
nuclear cell extracts for 3h at 4°C. After incubation, UV samples were UV crosslinked according to 17. 
Afterwards, Streptavidin M-270 Dynabeads (80 µL Slurry, Thermo Fisher) were incubated with cell 
complexes for 2h at 4°C. After 4 washing steps with the lysis buffer of the truCHIP chromatin 
Shearing Kit (Covaris, USA), beads were put into a new Eppendorf tube. For western analysis, beads 
were boiled in Laemmli buffer and proteins were separated by SDS-PAGE, followed by 
immunoblotting. For RNA analysis, RNA was extracted with TRIzol (Thermo Fisher). Afterwards, RNA 
purification was performed with the RNeasy Mini Kit (Qiagen). After reverse transcription, qRT-PCR 
was performed. For mass spectrometric measurements in order to reduce complexity, samples were 
eluted stepwise from the beads. First elution was performed with 5 M Urea, 2 mM DTT, 50 mM Tris 
pH 7.5, for 15 min. Thiols were alkylated with 57 mM chloracetamide for 20 min at RT in the dark. 
Beads were sedimented and supernatant was transferred to Microcon YM-30 (Millipore) spin filters 
(30 kDa cut-off) and centrifuged for 10 min. Proteins from beads and filters were digested overnight 
with 1 µg LysC (Wako) in 100 µL 2 M Urea, 50 mM Tris pH 7.5 and combined. Beads were washed 
with 100 µL ABC and supernatant was transferred to the digestion and the mixture was digested with 
1 µg Trypsin (Promega) overnight at RT. Remaining proteins on beads were eluted for 10 min at 95°C 
in 4% SDS, 50 mM HEPES pH 7.6, 100 mM NaCl, 10 mM DTT. Subsequently the standard protocol of 
filter aided sample preparation (FASP) was performed18 including RNase T1 (1000 U/µL, Thermo 
Scientific) and RNase A (4 µg/µL, Thermo Scientific) digestion using 1 µL each to elute crosslinked 
peptides. Peptides from both fractions were acidified by trifluoroacetic acid (TFA) to a final 
concentration of 0.1% and purified on multi-stop-and-go tips (StageTips) containing a stack of three 
C18-disks19. Peptides were resolved in 1% acetonitrile and 0.5% formic acid and further analyzed by 
Liquide chromatography/mass spectrometry (LC/MS).  Plasmid overexpression and peptide purification for mass spectrometry. 
Plasmid overexpression in HUVECs for searching small peptides was performed with the Neon 
electroporation system (Invitrogen) with the following plasmids: pcDNA3.1+MANTIS, pcDNA3.1+ 
(empty vector) and pcDNA3.1-GFP. Pellets of transfected HUVECs were resuspended in 50 µL 6M 
Guanidine hydrochloride (GdmCl), 50 mM Tris/HCl, pH 8.5, 10 mM Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) and incubated at 95°C for 5 min. Reduced thiols were alkylated with 40 mM 
chloroacetamide and samples were diluted with 25 mM Tris/HCl, pH 8.5, 10% acetonitrile to obtain a 
final GdmCl concentration of 0.6 M. Protein lysate was added to a 30 kDa cut-off filter unit and 
centrifuged. Flow-through was acidified with TFA to obtain a final concentration of 0.5%. In a parallel 
experiment, including the empty vector pcDNA3.1+, pcDNA3.1+MANTIS, but without pcDNA3.1GFP, 
the flow through was digested with 1 µg trypsin (Promega, sequencing grade) overnight at 37 °C. 
Digestion was stopped by adding TFA to a final concentration of 0.5 %. Acidified peptides were 
loaded on multi-stop-and-go tip (StageTip) containing six C18-disks. Purification and elution of 
peptides was performed as described19. Peptides were eluted in wells of microtiter plates, dried and 
resolved in 1% acetonitrile, 0.1 % formic acid and analyzed by LC/MS. Mass spectrometry. 
LC/MS was performed on Thermo Scientific™ Q Exactive Plus coupled to an ultra-high performance 
liquid chromatography unit (Thermo Scientific Dionex Ultimate 3000) via a Nanospray Flex Ion-Source 
(Thermo Scientific). Peptides were loaded on a C18 reversed-phase precolumn (Zorbax 300SB-C18, 
Agilent Technologies) followed by separation on in-house packed 2.4 µm Reprosil C18 resin (Dr. 
Maisch GmbH) picotip emitter tip (internal diameter 100 µm, internal diameter of the tip 10 µm, 15 
 
 
cm long, New Objectives) with a flow rate of 400 nL/min using a gradient from mobile phase A (4% 
acetonitrile, 0.1% formic acid) to 44% mobile phase B (80% acetonitrile, 0.1% formic acid) for lncRNA 
MANTIS binding protein analysis. For micropeptide identification, the peptides were eluted using 
gradient from 5% to 80% mobile phase B. Mass spectrometry (MS) data were recorded by data 
dependent Top10 acquisition (selecting the ten most abundant precursor ions in positive mode for 
high energy collision dissociation fragmentation (HCD)). The Full MS scan range was 300 to 2500 m/z 
with resolution of 70000 at m/z 200, and an automatic gain control (AGC) value of 3*106 total ion 
counts with a maximal ion injection time of 250 ms. Only higher charged ions (2+) were selected for 
MS/MS scans with a resolution of 17500, an isolation window of 2 m/z and an automatic gain control 
value set to 1*105 ions with a maximal ion injection time of 150 ms. First fixed mass was 110 m/z for 
the analysis of Mantis binding proteins. Full MS and MS/MS data were acquired in profile mode by 
Xcalibur software.  
 Mass spectrometry- Data analysis. 
X calibur Raw files were analyzed by proteomics software Max Quant (1.5.2.8)20. For the analysis of 
peptides without digestion the enzyme specificity was set to unspecific. For experiments with tryptic 
digestion the enzyme specificity was set to trypsin; missed cleavages were limited to 2. Acetylation of 
N-terminus (+42.01), carbamidomethylation (+57.02) and oxidation of methionine (+15.99) were 
selected as modification. Human reference proteome set from Uniprot (68506 entries, Download 8th 
April 2015) was supplemented with in silico predicted MANTIS ORFs and green fluorescent protein 
(GFP) ORFs and used for identification of peptides and proteins smaller than 30kDa in empty vector, 
MANTIS or GFP overexpressing HUVECs (Supplemental Table 6-9). In addition, a public available 
proteome dataset of HEK cells from a long online 2D SCX-RP UHPLC-MS/MS run (PXD00070521) from 
the PRIDE Database22 was analysed using the same supplemented database (Supplemental Table 
4&5). False discovery rate (FDR) was set to 1%.  
Supplemental Table 10 summarizes the data of the analysis of lncRNA MANTIS binding proteins 
obtained by database search of the human reference proteome set (68506 entries, Download 8th 
April 2015) and label free quantification from at least one identified peptide. The protein group file 
was uploaded to Perseus 1.5.1.6 and the data set was cleaned from reverse identifications, only 
identified by site and common contaminants. For label free quantification all proteins were quality 
filtered according to a minimum of three valid values in one group. For proteins with missing values 
in the other group a background value of half of the lowest value was imputed. Ratios between 
MANTIS and control were calculated from the average and log2 of the ratio was plotted against –
log10 p values. Protein with p<0.05 and at least 1.5 fold enriched in MANTIS fraction were 
considered as protein of interest. 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE22 partner repository with the dataset identifiers PXD005951 (HUVEC <30 kDa, 
Supplemental Tables 6&7, without trypsin) and PXD005957 (HUVEC <30 kDa, Supplemental Tables 
8&9, with tryptic digestion). 
 
 
RNA immunoprecipitation and protein immunoprecipitation.  
1x107 HUVECs were used per sample. Nuclei isolation was performed with the truCHIP™ Chromatin 
Shearing Kit (Covaris, USA) according to the manufacturers protocol without shearing the samples. 
After pre-clearing with 20 µL DiaMag Protein A and Protein G (Diagenode), 10% of the pre-cleared 
sample served as input and the lysed nuclei were incubated with BRG1, SMARCA5 or H3 antibodies 
or IgG alone for 12h at 4°C. The complexes were then incubated with 50 µL DiaMag Protein A and 
Protein G (Diagenode) beads for 3h at 4°C, followed by 4 washing steps in Lysis Buffer from the 
truCHIP™ Chromatin Shearing Kit (Covaris, USA). Prior to elution, beads were put into a new 
Eppendorf tube. For protein immunoprecipitation experiments, beads were boiled in Laemmli buffer 
and western analyses was performed. For RNA immunoprecipitation, RNA was extracted with TRIzol 
(Thermo Fisher) followed by RNA purification with the RNeasy Mini Kit (Qiagen), reverse 
transcription and qRT-PCR. RNA Fluorescence in-situ hybridization.  
Cells grown on fibronectin-coated coverslips were fixed in 4% PFA (in PBS, pH 7.4, 7 min at RT) and 
washed 3 times with PBS. Cells were permeabilized in PBS containing 0.5% Triton X-100 and 5 mM 
vanadyl complex (VRC, NEB) on ice for 10 min and again washed 3 times with PBS. Prior to 
hybridization, cells were rinsed once in 2xSSC. Hybridization was performed over night at 37°C in 
hybridization buffer (10% dextran sulfate, 50% formamide, 2xSSC, 400 µg E.coli tRNA, 0.02% RNase-
free bovine serum albumin, 2 mmol/L VRC) and 10 nmol/L 5’TYE-665 labelled locked nucleic acid 
(LNA) detection probe (Exiqon). Custom LNA detection probes were designed with the Exiqon LNA 
probe designer tool and had the following sequences: for MANTIS 5’-TGT AGA CAG ATA TGA GGC 
CAG T-3’ and for ß-Actin mRNA 5’-TCA TGA GGT AGT CAG TCA GGT-3’. The cells were then washed 4 
times for 15 min in buffer containing 2xSSC and 50% formamide and mounted in Vectashield 
containing DAPI. Images were taken with the laser scanning microscope LSM 510 META (Zeiss) and 
processed with ZEN 2011 software (Zeiss). In vitro protein synthesis and Coomassie staining. 
In vitro protein synthesis of DYR-DHFR, pcDNA3.1+MANTIS and pcDNA3.1+ (empty vector) was 
performed with the PURExpress kit (E6800, NEB) according to the manufacturer’s protocol. 
Afterwards, the reaction mixtures were boiled in Laemmli buffer, the proteins were separated with 
SDS-PAGE, the acrylamide gel was stained with Coomassie brilliant blue and finally the gel was 
destained using 50% methanol, 10% acetic acid until single bands appear. Chromatin Immunoprecipitation and RNA ChIP.  
Preparation of cell extracts, crosslinking and isolation of nuclei was performed with the truCHIP™ 
Chromatin Shearing Kit (Covaris, USA) according to the manufacturers protocol. The procedure was 
similar to 23. After sonification of the lysates with the Bioruptur Plus (10 cycles, 30 sec on, 90 sec off, 
4°C; Diagenode, Seraing, Belgium), cell debris was removed by centrifugation and the lysates were 
diluted 1:3 in dilution buffer (20 mmol/L Tris/HCl pH 7.4, 100 mmol/L NaCl, 2 mmol/L EDTA, 0.5% 
Triton X-100 and protease inhibitors). Pre-clearing was done with 20 µL DiaMag protein A and 
protein G coated magnetic beads slurry (Diagenode, Seraing, Belgium) for 45 min at 4°C. The samples 
were incubated as indicated over night at 4°C with the antibodies indicated. 5% of the samples 
served as input. The complexes were collected with 50 µL DiaMag protein A and protein G coated 
magnetic beads (Diagenode, Seraing, Belgium) for 3h at 4°C, subsequently washed twice for 5 min 
 
 
with each of the wash buffers 1-3 (Wash Buffer 1: 20 mmol/L Tris/HCl pH 7.4, 150 mmol/L NaCl, 0.1% 
SDS, 2 mmol/L EDTA, 1% Triton X-100; Wash Buffer 2: 20 mmol/L Tris/HCl pH 7.4, 500 mmol/L NaCl, 2 
mmol/L EDTA, 1% Triton X-100; Wash Buffer 3: 10 mmol/L Tris/HCl pH 7.4, 250 mmol/L lithium 
chloride, 1% Nonidet p-40, 1% sodium deoxycholate, 1 mmol/L EDTA) and finally washed with TE-
buffer pH 8.0. Elution of the beads was done with elution buffer (0.1 M NaHCO3, 1% SDS) containing 
1x Proteinase K (Diagenode, Seraing, Belgium) and shaking at 600 rpm for 1h at 55°C, 1h at 62°C and 
10 min at 95°C. After removal of the beads, the eluate was purified with the QiaQuick PCR 
purification kit (Qiagen, Hilden, Germany) and subjected to qPCR analysis. As a negative control 
primer targeting the GAPDH promoter was used.   
RNA-ChIP experiments were performed similar to the ChIP experiments, but with the following 
changes: Washing was performed in a modified washing buffer 3 without lithium chloride. After the 
proteinase K elution step, DNA was digested with DNase I during the purification procedure with the 
RNA Mini Kit (Qiagen, Hilden, Germany) and samples were reverse transcribed as indicated. Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE) and MNase treatment. 
FAIRE was performed similarly as described in 24. HUVECs were crosslinked with 1% formaldehyde for 
5 min, quenched with 125 mM glycine for 5 min, scraped, washed with PBS and lysed in 2 mL FAIRE 
buffer 1 (50 mM HEPES-KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% 
Triton X-100) at 4°C for 10 min followed by centrifugation (5 min, 16,000 xg, 4°C). Afterwards, cell 
pellets were resuspended and incubated in 2 ml FAIRE buffer 2 (10 mM Tris-HCl [pH 8.0], 200mM 
NaCl, 1 mM EDTA, 0.5 mM EGTA) for 10 min at 22°C followed by centrifugation (5 min, 16,000 xg, 
4°C). Cell pellets were resuspended in 400 µl FAIRE buffer 3 (10 mM Tris-HCl, [pH 8.0], 100 mM NaCl, 
1 mM EDTA, 0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine). Subsequently, 
samples were sheared (30 sec On, 90 sec Off, 10 cycles, 4°C) with a Bioruptor Plus  (Diagenode, 
Seraing, Belgium) to an average length of 200-400bp and cleared by centrifugation (5 min, 16,000 xg, 
4°C). 10% of each sample was used as input. Samples were further extracted with 
phenol/chloroform/isoamylalcohol (Roti Phenol/C/I) and the aqueous phase was collected and 
precipitated with EtOH over night. After resuspension in TE-Buffer, input and extracted DNA were de-
crosslinked at 65°C for 6 h and the DNA was purified with the QIAquick PCR purification kit (Qiagen, 
Hilden, Germany).  
For MNase experiments, which were performed similar to 25, but with several modifications, HUVECs 
were crosslinked identical to the FAIRE protocol, but lysed in 2mL MNase buffer 1 (50 mM HEPES-
KOH [pH 7.5], 10 mM NaCl, 3 mM MgCl2, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100) at 4°C for 10 
min followed by centrifugation (5 min, 16,000 xg, 4°C). Next, cell pellets were resuspended and 
incubated in 2 ml MNase buffer 2 (10 mM Tris-HCl [pH 8.0], 15 mM NaCl, 60 mM KCl, 0.1% sodium 
deoxycholate, 0.5% N-lauroylsarcosine) for 10 min at 22°C followed by centrifugation (5 min, 16,000 
xg, 4°C). After removal of the supernatant, cell pellets were washed in 2mL MNase buffer 3 (10 mM 
Tris-HCl [pH 8.0], 1mM CaCl2), centrifuged (2 min, 13,000 xg, 4°C), and the sedimented chromatin 
pellet was resuspended in 200 µl MNase buffer 3. 5% of each sample was used as input. Samples 
were digested with mononuclear Nuclease (Mnase, ThermoFisher) for 10min at 37°C and the 
reaction was stopped with stopping buffer (8.6% SDS, 7mM EDTA [pH 8.0). After proteinase K 
treatment for 30min at RT, samples were de-crosslinked at 65°C for 6 h and the DNA was purified 
with the QIAquick PCR purification kit (Qiagen, Hilden, Germany). 
 
 
Cloning of MANTIS mutants. 
To generate MTS-mut with the putative functional region of MANTIS into pcDNA3.1+, the region of 
MANTIS was PCR amplified with 5’-ATT TGG TAC CCA AAT GTC TTC AAG GTA TAA AAA TGT GGT CTA-
3’ and 5’- ATT TGG GCC CGT GCT GGA TGC AGA TAA TGT TTG ACT CCT-3’ and both, pcDNA3.1+ and 
the PCR fragment, were digested with Acc65I/ApaI prior to ligation and E.coli transformation.  
To generate the other mutants in a pcDNA3.1+ background, the full length pcDNA3.1+MANTIS was 
digested with either XbaI/Acc65I (for ΔN1), with BlpI/Acc65I (for ΔN2) or with Eco47III/ApaI (for ΔC), 
followed by Klenow Fill-In (for ΔN1 and ΔN2) or 3’-5’ exonuclease (for ΔC) treatments. After re-
circularization, all plasmids were verified by sequencing.  Cloning of pGL3_MANTIS_1kb and Luciferase Reporter Assay. 
To clone 1kb upstream of the MANTIS TSS into pGL3 luciferase reporter plasmid, genomic DNA was 
PCR amplified with 5’-CGG CAT GGT ACC CTA TGT CTG ACA CAT AGT AGA GCT TAA TAA AC-3’ and 5’-
ATT TGC TAG CTA GGC AAA AGA ACA GAA CAG CTC ACA GTC ACA GAG-3’. The resulting PCR product 
and pGL3 were digested with Acc65I/NheI, followed by ligation and DNA preparation. The final 
plasmid pGL3-MANTIS_1kb was verified by sequencing. HUVECs overexpressing JARID1B or a 
catalytically dead-mutant of JARID1B (pCMV-J1B-Mut) were transiently transfected with pGL3 or 1kb 
promoter of MANTIS in pGL3 with Lipofectamine 3000 (Thermo Fisher) according to the 
manufacturers protocol. PCMV-J1B-Mut as well as pCMV-J1B were kindly provided by K. Helin 
(University of Copenhagen, Denmark). Luciferase activity was determined with the assay kit from 
Promega (Mannheim, Germany) in a TECAN infinite M200OPro plate reader (Männedorf, 
Switzerland) and normalized to the empty pGL3 control vector (Promega). Proximity Ligation Assay.  
Proximity Ligation Assays (PLA) were performed as described in the manufacturer’s protocol (Duolink 
II Fluorescence, OLink, Upsalla, Sweden). Briefly, after siRNA knockdown in HUVEC, cells were fixed in 
phosphate buffered formaldehyde solution (4%), permeabilized with Triton X-100 (0.2%), blocked 
with serum albumin solution (3%) in phosphate buffered saline and incubated overnight with the 
antibodies indicated. Samples were washed and incubated with the respective PLA-probes for 1h at 
37°C. After washing, samples were ligated for 30 min (37°C). After an additional washing step, the 
amplification with polymerase was allowed for 100 min (37°C). The nuclei were stained using DAPI. 
Images were acquired by confocal microscope (LSM 510, Zeiss). BRG1 ATPase Assay.  
The ATPase Assay after immunoprecipitation with BRG1 antibodies precipitates was performed 
directly on magnetic beads as described in 26 and in the manufacturer’s protocol (Innova Biosciences, 
ATPase Assay Kit, Cambridge, UK). Assay for Transposase Accessibility (ATAC)-Sequencing. 
HUVECs were treated with siRNAs against Scrambled or MANTIS siRNA for 48h. 100.000 cells were 
used for ATAC library preparation using Tn5 Transposase from Nextera DNA Sample Preparation Kit 
(Illumina). The cell pellet was resuspended in 50 µL PBS and mixed with 25 µL TD-Buffer, 2.5 µL Tn5, 
0.5 µL 10% NP-40 and 22 µL H2O. The Cell/Tn5 mixture was incubated at 37°C for 30 min with 
occasional snap mixing. Transposase treatment was followed by 30 min incubation at 50°C together 
 
 
with 500 mM EDTA pH8.0 for optimal recovery of digested DNA fragments. To neutralize EDTA, 100 
µL of 50 mM MgCl2 was added followed by purification of the DNA fragments by MinElute PCR 
Purification Kit (Qiagen). Amplification of library together with indexing was performed as described 
elsewhere27. Libraries were mixed in equimolar ratios and sequenced on NextSeq500 platform using 
V2 chemistry. The samples were sequenced on Illumina NextSeq hardware and assessed for quality. 
Trimmomatic version 0.33 was employed to trim reads after a quality drop below a mean of Q20 in a 
window of 5 nt28. Only reads above 30 nt were cleared for further analyses. In order to normalize all 
samples to the same sequencing depth, 27 million reads per sample were randomly selected for 
further analysis. These were mapped versus the hg19 version of the human genome with STAR 
2.4.2a29 using only unique alignments to exclude reads with uncertain arrangement. The reads were 
deduplicated to avoid PCR artefacts leading to multiple copies of the same original fragment. The 
MUSIC peak caller (version from Dec. 2015)30 was employed in punctate mode to accommodate for 
the range of peak widths typically expected for ATAC-seq. The maximum qvalue was set to 0.2 and 
the p-value normalization window length was changed to 1500. Peaks overlapping ENCODE 
blacklisted regions (known misassemblies, satellite repeats) were excluded. Peaks were annotated 
with the promoter (TSS +- 5000 nt) of the gene most closely located to the centre of the peak based 
on reference data from GENCODE v19. In order to be able to compare peaks in different samples 
(scrambled and MANTIS siRNA), the resulting lists of significant peaks were overlapped and unified to 
represent identical regions. The counts per unified peak per sample were computed with 
BigWigAverageOverBed (UCSC Genome Browser Utilities, 
http://hgdownload.cse.ucsc.edu/downloads.html). Raw counts for unified peaks were submitted to 
DESeq2 for normalization31. Spearman correlations were produced to identify the degree of 
reproducibility between samples using R. To permit a normalized display of samples in IGV, the raw 
BAM files were normalized for sequencing depth (number of mapped deduplicated reads per 
sample) and noise level (number of reads inside peaks versus number of reads not inside peaks). Two 
factors were computed and applied to the original BAM files using bedtools genomecov resulting in 
normalized BigWig files for IGV. Raw data of ATAC-Seq is available at GEO datasets (GSE83427). 
 
 
Supplemental Table 1: List of primers for qRT-PCR. 
Name Species Forward Primer (5’-3’) Reverse Primer (5’-3’) 
ß-Actin Hs AAA GAC CTG TAC GCC AAC AC GTC ATA CTC CTG CTT GCT GAT 
MANTIS (n342419) Hs AAC TCC TGC TCC AAA CTC ACT C CCA GAG ACT TTC CAT TCT GAT G 
N337754 Hs GCT GGG AAT GTG TCC CTA AC GCT GGT AGC AAG CCA GTA AG 
N345337 Hs CAT TGT GGC CTC AGC AGA AG CCG CGA TAC CGT TTC TGA TG 
N332912 Hs GCC ACT GGC TTA TTC CAT AG CCT GTG TCT TCT CAC CAT TC 
N339736 Hs GCC TTG AAG CAG GTT AGA TG CCC TGA AGC AAC TGA TTG TC 
N406914 Hs GAC TCG TGG GTA CGC ATA GG TAC TGG TGG CGA GGT GAG AC 
JARID1B Hs, Mf TGA GGA TGA AGA TGC CAT CTG CC ACA GCG CAC ACA GAT GTA GTC TTC 
U12 snRNA Hs GCC CGA ATC CTC ACT GCT AA TCG CAA CTC CCA GGC ATC 
MEG3 Hs GAG TGT TTC CCT CCC CAA GG GCG TGC CTT TGG TGA TTC AG 
SOX18 Hs CAT GGT GTG GGC AAA GGA C GCC GGT ACT TGT AGT TGG G 
SMAD6 Hs CCT CTA TGC GGT GTA CGA C GAT GCC GAA GCC GAT CTT G 
SOD2 Hs CCC TGG AAC CTC ACA TCA AC GGC TGT AAC ATC TCC CTT GG 
COUP-TFII Hs CGC CTT TAT GGA CCA CAT ACG TCC ACA TGG GCT ACA TCA GAG 
ANXA4 Hs GCA GCA ATA TGG ACG GAG C CAG GTC CTG GGC ATC CTG TC 
GCML1 Hs CAG AAC AGG ACA GTG AGG TG CGA TTG GTG TAA GTT ACA AG 
snRNP27 Hs CTT CTC GAC TGA AAG AAA G CTG CCT GTA CTT CCT CTT C 
AAK1 Hs CAG AAG GGT CTA CGT GGA ATC CAG TTC CAG CAG AAA ATG AGG 
PRCP Hs TTT GCC TGC TTG GCC TAT C TAG CTC CAA CCC AGT GTT C 
IL6 Hs ACA GCC ACT CAC CTC TTC AGA ACG CAG CTC TGG CTT GTT CCT CAC TAC 
TUFT1 Hs AGC AGA AAG AGG CAG AAG TC CTT GGC AGT CAG CAT TGT TG 
PECAM1 Hs GCG GTA TTC AAA GAC AAC CC ATC ACC TTC ACC CTC AGA AC 
RNMT1 Hs GGA CCT GGG ATG TGG TAA AG CGC TGC TGA CAC TGT TTG AC 
SOX7 Hs CCA AGG ACG AGA GGA AAC G GCC GGT ACT TGT AGT TGG G 
HEY1 Hs GCC AGC ATG AAG CGA GCT C GGG TCA GAG GCA TCT AGT CC 
18S rRNA Hs CTT TGG TCG CTC GCT CCT C CTG ACC GGG TTG GTT TTG AT 
GAPDH Hs TGC ACC ACC AAC TGC TTA GC GGC ATG GAC TGT GGT CAT GAG 
MANTIS-mut Hs ATC TCC TGA CCT CGT GAT CC GGC TTG GTT GCT TCC GTA TG 
MANTIS  Mf AAC TCC TGC TCC AAA CTC ACT C TGA AGC AGC CTT GTT GTC 
GAPDH Mf TGC ACC ACC AAC TGC TTA GC GGC GTG GAC TGT GGT CAT GAG 
MANTIS Rn GGG TGG GTA CAC CTG GAA TC ACA GGA GGC TGC TGT CTG AG 
SOX18 Rn CCT TCT TCC CAC CGC CTT TG TGC CCA GGG TGC CAT AGT AG 
SMAD6 Rn GCA CGC AGT GGA GCT GAA AC GGA GAC AGC CGA GAA TAG GG 
COUP-TFII Rn ACA TCA TGG GCA TCG AGA AC GTG CTG CAT TCA ACA CGA AC 
ß-Actin Rn TGC CCA TCT ATG AGG GTT AC TCT CTT GCT CGA AGT CTA GG 
Hs, Homo sapiens; Mf, Macaca fascicularis; Rn, Rattus norvegicus 
 
Supplemental Table 2: List of primers for ChIP. 
Name Forward Primer (5’-3’) Reverse Primer (5’-3’) 
ßACTIN 826nt from TSS TCT GTG GCA CAT GGA GTC TTG GTC ACA CAG CCT GGG TCT GGG CCC AC 
GAPDH 612nt from TSS TGG TGT CAG GTT ATG CTG GGC CAG GTG GGA TGG GAG GGT GCT GAA CAC 
MANTIS 10-117nt after TSS AAC TCC TGC TCC AAA CTC ACT C TGA AGC AGC CTT GTT GTC 
MANTIS 684-773nt from TSS GCT AGG CCA GGT AGT TTG GCT ACC CTC CAG TTA GC 
MANTIS 352-471nt from TSS GCT CAA GCA CAG AAG AAG GTG CAC CTA AAG GGA AAG 
SMAD6 29-93nt up TSS TCT AGA CTG GCA TAT GAT GG TTT GTT CTC CTC AAA CGC ACA CTG 
SMAD6 1491-1586nt up TSS GTG TCT CAG TCC GAT CTT TC ACC CTT TGC TGA GCT TTA CC 
SMAD6 3031-3104nt up TSS TTT AAT CCG GCA TCG GCT AC AAG ACA CTG AGG CAC AAA GG 
SOX18 39-142nt up TSS AAT CCC GCC CGG CCT GAG AAG AAA G GAT ATA GCG GCT CAG GGC CAA TCG 
SOX18 586-669 up TSS TCT TTG TGG GCT CCG TCC AG CCT CAC TCC CAA ACC AAC TC 
SOX18 1022-1155nt up TSS CAC AGG CTC AGG GTC ACA AG CTC CAG GCA GGG TCA GAA TC 
COUP-TFII 3185-3265nt up 
TSS 
GAG CTC CAG TGT GGT GGA AG CCG TCC TCC AGG ATT CAT TG 
COUP-TFII 137-234nt up TSS GCT AAG TTG CAG CAG TCG TG GAG GGA ATG CGA TTT ATA GG 
COUP-TFII -534-617nt up 
TSS 
CCT CTC GCG GAG CCT TTA AGA GAC G ACA TCC CGC ACC CGA GGT TTC 
 
 
Supplemental Table 3: LncRNAs significantly altered in the Exon array after JARID1B knockdown
logFC p-value* logFC p-value* logFC p-value* logFC p-value* logFC p-value* logFC p-value*
NONCODE_id siJarid1b-1/siScr siJarid1b-1/siScr siJarid1b-2/siScr siJarid1b-2/siScr siJarid1b-1/siGFP siJarid1b-1/siGFP siJarid1b-2/siGFP siJarid1b-2/siGFP siJarid1b-1/siJarid1b-2 siJarid1b-1/siJarid1b-2 siScr/siGFP siScr/siGFP NONHSAT No. Chr. Pos. Hg19
n342419 1.958 0 1.304 1.00E-05 1.856 0 1.202 2.00E-05 0.653 0.00248 -0.102 0.55311 NONHSAT071358, Mantis chr2:70,016,684-70,026,080
n345337,n339305 -0.333 0.00941 -0.76 2.00E-05 -0.363 0.00567 -0.79 1.00E-05 0.427 0.00199 -0.03 0.77801 NONHSAT143945   chr16:81,417,177-81,423,143
n337754 0.539 0.04837 0.631 0.02474 1.625 4.00E-05 1.718 2.00E-05 -0.093 0.70975 1.086 0.00098 NONHSAT137492   chrX:71,370,734-71,373,135
n384507,n345653 1.798 0 0.842 0.00028 1.937 0 0.98 8.00E-05 0.957 0.0001 0.139 0.40283 NONHSAT098244   chr4:128,758,922-128,761,883
n370434 0.598 0.01685 0.667 0.00942 1.177 0.00018 1.247 0.00011 -0.07 0.74859 0.58 0.01964 NONHSAT125246    chr8:16325251-16353693
n341767 -0.557 0.00314 -1.045 2.00E-05 -0.332 0.04583 -0.82 0.00018 0.488 0.00708 0.225 0.15533 NONHSAT134432    chr9:118,954,208-118,954,799
n407688,n341993,n335521,n335610,n380837,n380732 0.369 0.03381 0.408 0.02174 0.637 0.00158 0.675 0.00105 -0.038 0.8069 0.268 0.10648 NONHSAT030138   chr12:98,906,751-98,910,200
n343078,n343081 0.55 0.00032 0.342 0.0083 0.652 8.00E-05 0.444 0.00159 0.208 0.07623 0.102 0.35628 NONHSAT024403    chr11:117,162,062-117,162,865
n345157,n341158 0.288 0.01255 0.28 0.01437 0.384 0.00221 0.377 0.00252 0.007 0.94039 0.096 0.33879 NONHSAT025148   chr11:130731861-130744709
n338988 0.757 0.00164 0.716 0.00239 0.722 0.00226 0.68 0.00333 0.041 0.82466 -0.035 0.85043 NONHSAT075123   chr2:160,626,484-160,629,028
n341701 0.734 0.00825 1.058 0.00074 0.507 0.04782 0.832 0.0039 -0.324 0.18203 -0.227 0.34053 NONHSAT131922   chr9:77,109,925-77,111,785
n385261 1.162 0.0002 0.833 0.00235 1.094 0.00032 0.765 0.00407 0.329 0.1474 -0.068 0.7541 NONHSAT122865   chr7:115,893,170-115,895,118
n339119 0.416 0.01748 0.521 0.00506 0.403 0.02051 0.507 0.00592 -0.105 0.49593 -0.013 0.92958 NONHSAT076663   chr2:210,887,131-210,889,246
n365169,n365168,n365170 0.421 0.04413 0.566 0.01111 0.485 0.02405 0.629 0.00605 -0.144 0.45097 0.064 0.73638 not found in noncode
n339736 0.315 0.0152 0.291 0.02238 0.39 0.00459 0.366 0.00671 0.024 0.83099 0.075 0.5094 NONHSAT093906   chr3:187,868,994-187,871,876
n386426,n385076,n345961 0.339 0.01504 0.34 0.01476 0.39 0.00691 0.392 0.00678 -0.001 0.9918 0.052 0.66772 NONHSAT118940   chr7:5,862,791-5,887,232
n383794,n409113 -0.617 0.0008 -0.758 0.00016 -0.3 0.04684 -0.442 0.00721 0.142 0.31148 0.316 0.03782 NONHSAT076543   chr2:206980285-206982288
n339922 -0.765 0.0088 -0.544 0.04477 -0.999 0.00165 -0.778 0.00801 -0.221 0.37643 -0.234 0.35064 NONHSAT059854    chr18:71,589,174-71,589,866
n366331,n339642 1.226 0.00165 0.815 0.01853 1.36 0.00078 0.949 0.0083 0.411 0.19055 0.134 0.65835 NONHSAT092690   chr3:150,180,819-150,184,174
n341101 0.641 0.01952 0.816 0.00519 0.573 0.03251 0.749 0.00861 -0.176 0.46796 -0.067 0.77823 NONHSAT023724   chr11:94,276,131-94,277,949
n382502,n345800 0.343 0.00408 0.357 0.00314 0.284 0.01218 0.298 0.0093 -0.014 0.88125 -0.059 0.54524 NONHSAT041825   chr15:40,616,681-40,618,914
n342269,n378723,n384120,n378392,n377791 -0.232 0.02924 -0.268 0.01462 -0.253 0.01937 -0.289 0.00968 0.036 0.70259 -0.021 0.82005 NONHSAT084403   chr22:25,675,290-25,679,061
n406914 0.491 0.01442 0.582 0.00553 0.428 0.02776 0.52 0.01059 -0.092 0.5968 -0.062 0.71842 NONHSAT090901   chr3:101395274-101398057
n381616 0.524 0.00687 0.579 0.00371 0.426 0.02062 0.482 0.01101 -0.056 0.72983 -0.098 0.5465 NONHSAT018224   chr11:17,353,589-17,371,521
n332912 -1.492 0.00103 -0.862 0.02638 -1.634 0.00052 -1.003 0.01247 -0.631 0.08691 -0.142 0.68038 NONHSAT127418    chr8:81,454,721-81,455,338
n374751,n374961 0.508 0.00778 0.382 0.03244 0.579 0.00352 0.453 0.01448 0.126 0.43618 0.071 0.65712 NONHSAT041932  chr15:41,578,207-41,598,741
n345507,n365311 1.209 5.00E-05 0.723 0.00262 1.024 0.0002 0.538 0.0149 0.486 0.02426 -0.185 0.34012 NONHSAT076128   chr2:192,556,795-192,583,257
n339129,n365326,n345568,n383805 -0.417 0.01382 -0.435 0.01106 0.426 0.01241 0.408 0.01552 0.018 0.90199 0.843 0.00011 NONHSAT076795   chr2:217,081,612-217,084,915
n383576 0.27 0.02432 0.323 0.00985 0.233 0.04549 0.286 0.0185 -0.053 0.61968 -0.037 0.7284 NONHSAT068750    chr2:3664890-3665294
n345421 0.705 0.00282 0.647 0.00482 0.562 0.01098 0.505 0.01905 0.057 0.76123 -0.143 0.45161 NONHSAT008565   chr1:193,224,754-193,233,744
n385488,n385489,n377649 -0.554 0.01259 -0.85 0.00083 0.794 0.00136 0.499 0.02135 0.295 0.13983 1.349 2.00E-05 NONHSAT130385   chr9:21,454,267-21,559,697
n368145, n368144 0.764 0.00604 0.735 0.00759 0.625 0.01804 0.596 0.02271 0.029 0.89888 -0.139 0.54779 NONHSAT103689    chr5:130588746-130591276
n340207 0.492 0.01034 0.465 0.01405 0.433 0.01993 0.406 0.02707 0.028 0.86563 -0.059 0.71785 NONHSAT098131   chr4:121,843,097-121,844,760
n340820,n333701,n334084 0.568 0.00037 0.376 0.00642 0.477 0.00139 0.285 0.02738 0.192 0.11372 -0.092 0.42886 NONHSAT107192   chr6:3,751,345-3,754,105
n341073 1.623 1.00E-05 -0.569 0.01958 1.673 1.00E-05 -0.518 0.03012 2.191 0 0.051 0.81204 NONHSAT023193   chr11:76,512,704-76,515,138
n339657 -0.333 0.04722 -0.372 0.02975 -0.329 0.04924 -0.368 0.03104 0.039 0.79699 0.004 0.98117 NONHSAT079464   chr20:33,576,778-33,578,801
n332967,n332785 0.908 0.0013 0.819 0.00265 0.598 0.01647 0.508 0.03486 0.089 0.67963 -0.31 0.16963 NONHSAT106849    chr6:2,887,744-2,888,137
n410602 1.259 0.00286 0.846 0.02591 1.198 0.00393 0.786 0.03591 0.413 0.23483 -0.061 0.85642 NONHSAT106824   chr6:2,877,747-2,894,368
n338125 -0.576 0.00407 -0.595 0.00329 -0.356 0.0463 -0.376 0.03727 0.02 0.9035 0.219 0.1944 NONHSAT005108    chr1:110,856,618-110,857,022
n367832 0.556 0.0092 0.558 0.00904 0.411 0.03941 0.413 0.03873 -0.002 0.99224 -0.145 0.4277 NONHSAT105249    chr5:174,178,307-174,277,728
n371473 0.396 0.01918 0.509 0.0048 -0.45 0.00992 -0.336 0.03984 -0.113 0.44785 -0.845 0.00012 NONHSAT138671   chrX:134,169,666-134,174,761
n366808,n366809 -0.37 0.00723 -0.29 0.02588 -0.341 0.01157 -0.26 0.04141 -0.081 0.48547 0.03 0.79423 NONHSAT095597    chr4:14,166,079-14,244,437
n342910,n373367 -0.562 0.02968 -0.547 0.03348 -0.534 0.03686 -0.519 0.04156 -0.015 0.94663 0.028 0.9041 NONHSAT032007   chr12:131,780,414-131,783,039
n340117,n345640 -0.712 0.01843 -0.713 0.01825 0.589 0.04276 0.588 0.04318 0.001 0.99562 1.301 0.00039 NONHSAT096887    chr4:75,144,014-75,196,255
n337636 -0.554 0.00207 -0.464 0.00636 -0.401 0.01425 -0.311 0.04512 -0.09 0.52702 0.153 0.2905 NONHSAT000265   chr1:1,185,157-1,186,714
* unadjusted p-values
Supplemental Table 11 Fold changes in MANTIS Illumina Array
log2 FC log2 FC log2 FC pValue Only genes in LNA MANTIS/CTL p<0.05 are shown 
SYMBOL LNA CTL/CTL LNA MANTIS/MANTIS LNA MANTIS/CTL LNA MANTIS/CTL
SMAD6 1.1561 1.01 -1.6174 0.049419463
SOX18 0.5095 0.3553 -1.6055 0.000911108
PECAM1 -0.1987 -0.9706 -1.5641 0.041417478
PRCP -0.401 -0.8392 -1.3299 0.030139569
GIMAP4 -0.433 -0.9127 -1.2437 0.012065604
ANGPT2 -0.0936 -0.3604 -1.13 0.004270938
ALDH1A1 -0.5833 -0.3776 -1.0719 0.015591465
MALL 0.304 -0.0058 -1.0499 0.001073482
NOS3 -0.1867 -0.1007 -1.0472 0.002312621
HEY1 0.6987 0.845 -1.043 0.039092342
C5orf13 -0.2936 -0.4864 -1.0315 0.030618566
SNORA18 -0.0992 -0.1593 -1.0269 0.003728965
PAFAH1B3 -0.3748 -0.7998 -1.024 0.013534942
FAM69B -0.0469 -0.1874 -1.0153 0.010340234
MARCH3 0.1515 -0.5221 -0.9947 0.033097747
LOC100134073 0.0459 -0.563 -0.9873 0.012528664
RGS5 0.1025 -0.0799 -0.983 0.049646578
PGF 0.4505 0.1948 -0.9803 0.033394811
FAM108C1 0.2162 0.0229 -0.9692 0.004681451
APLN -0.3375 -0.7283 -0.9689 0.009693627
LOC100133609 0.2875 -0.5401 -0.9655 0.049060657
ESAM -0.0022 -0.4335 -0.9554 0.003777405
MGC61598 0.4377 0.337 -0.9322 0.004973449
NOX4 -0.2557 -0.3635 -0.9194 0.007961236
HHIP -0.1925 -0.771 -0.9101 0.046134658
HYAL2 -0.0776 -0.32 -0.9043 0.040167421
ID1 0.7816 0.4328 -0.8975 0.013789861
C1QTNF5 -0.1064 0.1579 -0.8906 0.01397281
NME4 -0.2175 -0.7779 -0.8885 0.048793714
PRKCDBP 0.2349 0.2029 -0.8833 0.002342542
SOX4 0.0749 0.1378 -0.8769 0.000226235
TMEM106C -0.2548 -0.1714 -0.8701 0.036679531
HOXA9 0.3485 0.3322 -0.866 0.000346309
EMCN -0.0377 -0.1015 -0.8585 0.038984772
C13orf15 0.4017 0.1091 -0.8515 0.001522545
RALA -0.1846 -0.5095 -0.8433 0.028293307
PABPC1 0.0699 -0.5026 -0.8429 0.028995255
FLNB 0.2294 -0.0812 -0.834 0.039002148
TUBB3 -0.0573 -0.449 -0.8331 0.00260934
TM4SF18 0.0094 -0.062 -0.8317 0.006458019
MLLT11 0.1275 -0.2401 -0.8269 0.00349254
C8orf55 -0.2877 -0.4605 -0.8054 0.001121326
VASH1 0.0851 -0.088 -0.8043 0.049790294
LOC341315 0.1048 -0.0412 -0.8021 0.020795379
MORF4L2 0.0824 -0.6244 -0.8016 0.037717091
ITGA5 -0.2145 -0.7646 -0.7717 0.042025119
MAP3K1 0.0638 0.1137 -0.7712 0.018525703
PALMD -0.1344 -0.2475 -0.7668 0.034643309
PECI -0.0032 -0.213 -0.7635 0.000773168
GIMAP7 -0.2692 -0.2728 -0.7598 0.024315393
ATP6V0E2 -0.1007 -0.454 -0.7541 0.046214878
TNFAIP8L3 0.2564 0.1443 -0.7531 0.015559595
GIMAP8 -0.1526 -0.4279 -0.7515 0.002535429
NDUFS5 -0.1681 -0.6424 -0.7319 0.034357289
P15RS -0.1277 -0.2796 -0.7281 0.016820365
LYPD1 -0.1104 -0.4828 -0.7188 0.006670455
SNORA8 -0.0652 0.0637 -0.7157 0.018332064
MIF -0.1973 -0.543 -0.7135 0.00693651
FAM127A 0.067 -0.1606 -0.7127 0.005125124
KIAA0114 -0.0157 0.2323 -0.7104 0.000772081
LOC648470 -0.2769 -0.5216 -0.7008 0.039072032
MAGED1 -0.0784 -0.3123 -0.6988 0.00843239
HN1 0.0398 -0.0905 -0.6924 0.000236116
ENC1 0.134 0.1922 -0.6903 0.001293902
TRIP13 0.0087 -0.4836 -0.6831 0.026284928
LOC390466 -0.1016 -0.4783 -0.681 0.025051642
ARPC1A 0.021 -0.3566 -0.6804 0.04472876
CTXN1 -0.1453 -0.2775 -0.679 0.000792881
JAG2 -0.0271 -0.0368 -0.672 0.031718476
LOC100130561 0.0355 -0.2895 -0.6716 0.009281159
GIMAP6 -0.1459 -0.2426 -0.6709 0.003906397
LOC729217 -0.1392 -0.2599 -0.6689 0.000696312
RPS27L -0.0398 -0.1021 -0.6631 0.000434648
FHOD1 0.1702 -0.1381 -0.6616 0.03656389
ENG 0.0612 -0.0271 -0.6597 0.009996997
MYO10 0.3259 0.1023 -0.658 0.011664167
EPHB4 -0.0874 -0.078 -0.652 0.00994254
TNFRSF21 -0.0121 -0.2101 -0.6511 0.00046991
DAAM1 0.2026 -0.0122 -0.6506 0.045490685
NPTX1 -0.0603 -0.09 -0.6475 0.006497759
LSM2 -0.055 -0.2901 -0.6464 0.003635162
PMP22 -0.0836 -0.4925 -0.6453 0.013199214
LOC646723 -0.1931 -0.2969 -0.645 0.001248048
LOC646576 0.1961 -0.2634 -0.6448 0.020273228
KCTD12 0.0504 0.0975 -0.6443 0.009775733
GNPDA1 -0.1918 -0.3487 -0.6439 0.001113003
FAM89B 0.1262 -0.0593 -0.6437 0.036632138
NGFRAP1 -0.2013 -0.3603 -0.6433 0.006294325
C14orf78 0.1282 -0.0628 -0.6402 0.025446357
LDHB 0.0252 -0.2561 -0.6399 0.007146078
MGST2 0.0775 0.0861 -0.6351 0.004137391
ST3GAL6 0.0246 -0.0384 -0.633 0.005872713
AK3 0.0135 0.0741 -0.6327 2.77516E-06
NUAK1 0.3483 0.1948 -0.6309 0.001145214
RCN2 0.1176 -0.0859 -0.6296 0.001923188
LOC100132863 0.3057 0.099 -0.6291 0.003127593
SOX7 0.0582 0.1077 -0.6287 0.000678402
HOXA5 0.0283 0.0862 -0.6282 0.002126835
FAM98A 0.0892 -0.2465 -0.6264 0.020132871
METTL3 -0.117 -0.2797 -0.6264 0.01091542
PDE4B -0.0641 -0.1216 -0.6246 0.041477389
APEX1 -0.0504 -0.3464 -0.6226 0.016743204
HNRNPA0 0.0563 0.0291 -0.6209 0.000390443
NT5DC2 -0.0235 -0.0466 -0.619 0.024496967
PSME3 0.0968 -0.2002 -0.6187 0.020042719
EBPL -0.2016 -0.3733 -0.6184 0.001808879
PEBP1 0.0231 -0.0976 -0.6094 0.00026006
CDK4 -0.2332 -0.1077 -0.6088 0.000905134
CALM3 0.0275 -0.2625 -0.6081 0.005162126
UCHL1 -0.3015 -0.3518 -0.6076 3.56872E-06
NR2F2 0.105 0.106 -0.6041 1.75662E-07
PLSCR3 -0.2617 -0.3901 -0.6035 0.004215018
CDK2AP1 -0.0832 -0.1879 -0.603 0.000162248
HEXB 0.2048 -0.2188 -0.6019 0.014063224
C20orf108 -0.0317 0.0377 -0.6007 2.44223E-05
PDCD1LG2 -0.0265 0.1537 0.6001 0.008550807
TYMP 0.0673 0.0459 0.6017 0.000155502
CCNYL1 0.0149 -0.1054 0.6031 0.016741524
SLCO4A1 0.0587 0.2324 0.6072 0.028420552
P2RX7 0.1846 0.1123 0.6078 0.02403089
TMUB2 0.0907 0.2581 0.6124 0.03772084
SUSD1 0.3268 0.3733 0.6128 0.000287069
SAP130 0.2728 0.2396 0.6135 0.000113231
FAT1 0.0598 0.2767 0.6136 0.004755863
AFF3 0.2516 0.3837 0.6219 0.02197693
GLIPR1 0.0906 0.4081 0.623 0.018559113
HCG4 0.011 -0.2459 0.6236 0.019919708
ACSL1 0.4925 0.4181 0.6253 0.003860924
SFRS17A 0.2314 0.4223 0.6265 0.001961199
STX5 0.2998 0.2509 0.6287 0.021080203
LOC399491 0.3856 0.5981 0.6315 0.003697023
SESN2 0.0058 0.3035 0.6344 0.015513135
LY6E -0.1839 -0.2809 0.638 0.034443777
FLNC 0.2753 0.3503 0.6401 0.001201444
NFE2L1 0.2439 0.2961 0.6416 0.000361724
KIF13B 0.2872 0.2397 0.6417 0.0379021
WDR51B 0.0651 0.2958 0.6439 0.044226404
TRIM26 0.0727 -0.0569 0.6484 0.001568771
LOC728734 0.1634 0.4133 0.6491 0.005298515
GMPR -0.2244 -0.1709 0.6494 0.001520639
TAP2 -0.0847 -0.0923 0.6552 2.27853E-06
LOC100128274 -0.0531 0.0244 0.6555 0.012930846
UNC93B1 -0.0481 -0.1954 0.6556 0.020466199
NFIX -0.0275 0.2217 0.6561 0.029167345
DDX58 -0.0036 -0.0723 0.6585 0.002466053
DDX60 -0.0279 0.0367 0.6589 0.005995079
RBCK1 0.2974 0.4213 0.6601 0.000782051
LAMC2 -0.1532 -0.4696 0.6668 0.022305654
APOBEC3G 0.0103 -0.034 0.6669 0.038914594
TNFAIP2 0.0946 -0.0954 0.67 0.002908611
BATF2 -0.3191 -0.3795 0.6722 0.018561273
HTATIP2 -0.0676 0.3626 0.6778 0.023654325
PSMB8 0.0517 -0.0243 0.6788 0.038225559
LOC440341 0.1636 0.5731 0.6897 0.021025068
TMEM123 0.07 0.1086 0.692 0.021370576
LOC440353 0.0964 0.3886 0.6949 0.014742289
MEG3 0.4335 0.5447 0.6951 0.005046136
LOC653496 0.4547 0.4001 0.6955 3.89793E-05
MX1 -0.0507 -0.0923 0.6993 6.29272E-05
LAMP3 0.0583 0.4338 0.6999 0.037939815
C1QTNF1 0.1648 0.0435 0.7019 0.000561974
LOC389386 0.0138 -0.1847 0.7025 0.004055299
OSBPL5 0.1137 0.1226 0.7101 0.025446114
CXCL1 0.2959 0.1296 0.7153 0.001864448
GBP2 0.3699 0.389 0.724 0.000729145
LOC728888 0.237 0.3524 0.7261 0.00138053
EPB41L5 0.1127 0.5119 0.7273 0.01956718
LOC100132247 0.1085 0.2703 0.7282 0.000878813
VPS37D 0.2127 0.3642 0.7337 0.029037844
TNIP2 0.0804 0.2143 0.7353 0.037033299
OGFRL1 0.038 -0.1413 0.736 0.037225797
CENTA1 0.2314 0.3675 0.7404 0.000592525
CCNDBP1 0.1322 0.2845 0.7409 0.025333231
LOC399959 0.1803 0.4656 0.7426 0.00429703
GLS 0.155 0.1548 0.7426 0.010090964
PARP9 0.0245 -0.0237 0.7518 0.00346676
TAP1 -0.2265 -0.0981 0.7527 0.03537523
CCDC136 0.3257 0.2826 0.7528 0.000157284
SERPINB1 0.3839 0.5602 0.7564 0.041973012
C1orf24 0.4802 0.4792 0.7566 0.01335912
STAT2 -0.2058 -0.325 0.7647 0.002097844
LOC440348 0.1421 0.3993 0.7706 0.006697211
VEGFC 0.2048 0.0352 0.7718 0.000693801
ADORA2A 0.132 0.3198 0.7791 0.001033894
NRIP3 0.4877 0.6989 0.7817 0.045822164
WARS -0.0247 0.0364 0.7893 0.012058284
DDX60L 0.107 -0.0047 0.7935 0.00182492
SLIT2 0.0789 -0.2097 0.7937 0.024408822
TNIP1 0.3377 0.1633 0.7967 0.01063807
ABCA1 0.4767 0.0618 0.7997 0.036489374
PLEKHA4 -0.0677 -0.0858 0.8096 0.000155041
USP36 0.2724 0.2401 0.815 0.000830131
DENND5A 0.3476 0.3593 0.8186 0.001919442
NPIP 0.196 0.5886 0.8269 0.011833527
MIR155HG -0.1953 -0.3135 0.8297 0.010465328
PLEKHO2 0.0736 0.3121 0.8391 0.002055338
GCH1 -0.0096 0.0012 0.8561 0.001253082
TMEM62 -0.139 0.2348 0.8611 0.020331442
VIP 0.0585 0.5214 0.8624 0.019840837
TDRD7 0.1734 0.1877 0.8628 0.008723408
FAM129A 0.6501 0.5121 0.8642 0.008485159
GFPT2 0.2753 0.1248 0.865 0.037925761
IL20RB -0.0584 0.4708 0.8715 0.036059779
TNFRSF9 0.2811 0.4349 0.8778 0.000767915
TMEFF2 0.2321 0.243 0.8807 2.42382E-05
LOC284023 0.1425 0.3188 0.885 0.001418701
IL1B -0.0095 -0.5985 0.9069 0.044979038
H2AFJ 0.1555 0.4318 0.9082 0.030275281
LOC643384 0.0608 -0.2756 0.922 0.022908581
UBE2L6 0.1161 -0.0073 0.9301 0.000641423
VAV3 0.2048 0.6347 0.9317 0.022471945
ALCAM 0.2509 0.1504 0.9327 0.032288239
CSF3 -0.0695 -0.1114 0.9365 2.93058E-06
CRTAC1 0.0192 -0.1172 0.9372 0.001281841
CFB -0.1566 -0.0755 0.9494 0.02899721
TAGLN 0.3533 0.3299 0.9724 0.015365603
NFKBIZ -0.2813 -0.134 0.981 0.000286285
LITAF 0.1446 0.1092 1.0199 0.029107598
RUNX3 0.0557 0.0297 1.03 0.047029744
RIPK2 0.0263 -0.035 1.0372 0.002766834
IFI35 -0.038 -0.1412 1.0705 0.041496787
ACTA2 -0.0419 0.1377 1.0956 0.01666818
CXCL2 -0.7209 -0.743 1.126 0.027534636
DHX58 0.0927 0.0781 1.1365 0.004506941
PIM2 0.1314 0.4335 1.1509 0.040245254
CSNK2A2 0.3108 0.4882 1.1582 0.018757491
CEBPD -0.0811 -0.2162 1.2433 0.047070744
ECGF1 0.0541 -0.0193 1.2479 0.041549722
TNFAIP6 0.3277 0.2127 1.309 0.045410978
GBP5 0.2085 0.2947 1.3121 0.025146063
SOD2 0.1372 0.2037 1.3218 0.004020659
HIST1H1C 0.5419 0.2275 1.3469 0.041908563
RNMT 0.5776 0.5214 1.3968 0.020987663
HIST2H2BE 0.0295 0.8312 1.4068 0.032585775
HIST1H2AC 0.2636 0.6215 1.41 0.041687472
TUFT1 0.2044 0.0576 1.4615 0.000746265
IL6 0.1239 0.0298 1.5319 0.019187988
NKD2 0.3482 0.2503 1.5339 6.17053E-05
CSF2 -0.329 -0.485 1.5825 0.000360621
Supplemental Table 12: Full gene ontology (GO) analysis made with Gorilla with the genes upregulated after MANTIS depletion in the Illumina Bead-Chip array.
GO term Description P-value
GO:0043207 response to external biotic stimulus 3.45E-11
GO:0009607 response to biotic stimulus 7.63E-11
GO:0002376 immune system process 1.58E-10
GO:0006952 defense response 1.36E-09
GO:0009605 response to external stimulus 1.43E-08
GO:0019221 cytokine-mediated signaling pathway 1.50E-08
GO:0002684 positive regulation of immune system process 7.92E-08
GO:0002682 regulation of immune system process 8.16E-08
GO:0006955 immune response 1.09E-07
GO:0031347 regulation of defense response 2.59E-07
GO:0002237 response to molecule of bacterial origin 3.43E-07
GO:0051704 multi-organism process 3.91E-07
GO:0051707 response to other organism 6.53E-07
GO:0006954 inflammatory response 7.53E-07
GO:0009615 response to virus 1.09E-06
GO:0032103 positive regulation of response to external stimulus 1.43E-06
GO:0032496 response to lipopolysaccharide 1.72E-06
GO:0032101 regulation of response to external stimulus 2.17E-06
GO:0071219 cellular response to molecule of bacterial origin 3.45E-06
GO:0002697 regulation of immune effector process 3.94E-06
GO:0050921 positive regulation of chemotaxis 4.67E-06
GO:0050776 regulation of immune response 5.97E-06
GO:0098542 defense response to other organism 6.90E-06
GO:0071216 cellular response to biotic stimulus 8.63E-06
GO:0045088 regulation of innate immune response 9.99E-06
GO:0050896 response to stimulus 1.29E-05
GO:0048520 positive regulation of behavior 1.30E-05
GO:0002688 regulation of leukocyte chemotaxis 1.51E-05
GO:0008285 negative regulation of cell proliferation 1.92E-05
Supplemental Table 13: Full gene ontology (GO) analysis made with Gorilla with the genes downregulated after MANTIS depletion in the Illumina Bead-Chip array.
GO term Description P-value
GO:0001525 angiogenesis 1.37E-06
GO:1901342 regulation of vasculature development 2.25E-05
GO:0001937 negative regulation of endothelial cell proliferation 2.98E-05
GO:0010596 negative regulation of endothelial cell migration 4.29E-05
GO:0040011 locomotion 4.75E-05
GO:0042981 regulation of apoptotic process 6.83E-05
GO:0043067 regulation of programmed cell death 7.63E-05
GO:0045765 regulation of angiogenesis 1.04E-04
GO:0032233 positive regulation of actin filament bundle assembly 1.07E-04
GO:0042127 regulation of cell proliferation 1.22E-04
GO:0048646 anatomical structure formation involved in morphogenesis 1.38E-04
GO:0050678 regulation of epithelial cell proliferation 1.44E-04
GO:0010633 negative regulation of epithelial cell migration 1.51E-04
GO:0065008 regulation of biological quality 1.57E-04
GO:0010941 regulation of cell death 1.66E-04
GO:0001936 regulation of endothelial cell proliferation 1.77E-04
GO:0016477 cell migration 1.85E-04
GO:0043542 endothelial cell migration 1.91E-04
GO:0043488 regulation of mRNA stability 2.06E-04
GO:0043537 negative regulation of blood vessel endothelial cell migration 2.45E-04
GO:0043487 regulation of RNA stability 2.56E-04
GO:0007167 enzyme linked receptor protein signaling pathway 2.74E-04
GO:0043065 positive regulation of apoptotic process 2.82E-04
GO:0032268 regulation of cellular protein metabolic process 2.99E-04
GO:0043068 positive regulation of programmed cell death 3.04E-04
GO:0051495 positive regulation of cytoskeleton organization 3.14E-04
GO:0043534 blood vessel endothelial cell migration 3.61E-04
GO:0071156 regulation of cell cycle arrest 3.88E-04
GO:0050680 negative regulation of epithelial cell proliferation 4.39E-04
GO:0010604 positive regulation of macromolecule metabolic process 4.40E-04
GO:0048870 cell motility 4.54E-04
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Supplemental Figure 1: (A) Full Affymetrix Exon‐Array heat map comparing siJARID1B‐1/siScr, siJARID1B‐2/siScr, siJARID1B‐1/siGFP, siJARID1B‐2/siGFP,
siJARID1B‐1/siJARID1B‐2 as well as siScr/siGFP levels of HUVEC batches 1‐3. Scale bar shows colour code from ‐2.0 (blue) to 2.0 (yellow) log2 fold change. Please
see supplemental table 3 for more information about these lncRNAs. (B) SiRNA knockdown with siScr, siJARID1B‐1 and siJARID1B‐2 in HUVEC and qRT‐PCR of
lncRNAs indicated. n=6, paired t‐test. (C) QRT‐PCR measurements of n342419 (MANTIS) and n406419 expression in HUVEC. Data is shown in log2 scale relative
to JARID1B RNA level. n=12. (D) Luciferase reporter assay of HUVECs transfected with an active JARID1B (J1B) or catalytically inactive JARID1B mutant (J1B Mut)
plasmid and a n342419 1kb promoter plasmid. n=4, unpaired t‐test. RLU, relative luminescence units. (E) Scheme of the genomic locus of MANTIS. Numbers
indicate genomic position (GRCh37/hg19). (F) Open reading frames determined by the RiboTaper14 (Ribosome profiling) method from RiboSeq data in HEK293.
The UCSC genome browser profile shows the genomic locus of MANTIS. (G) Prediction of the coding potential with CPAT15. (H) In vitro translation products
performed with the PUREexpress protein synthesis kit (NEB) from positive control (DYR), MANTIS (MTS) and negative control (NC) stained with Coomassie. M,
protein ladder. (I) Expression level of MANTIS in different cell types. Data is normalized to HUVEC batch 1. n=6. Error bars are defined as mean +/‐ SEM. *P<0.05.
050
100
150
MTSCTL
*N
o.
 o
f
ce
lls
 m
ig
ra
te
d
HG
0
5
10
15
MTSCTL
*
MTSCTL
VEGF-A - +
*
siRNA
No
. o
f t
ip
 c
el
ls
+VEGF-A
-VEGF-A
siMTS-YFPCTL-CFP MergeI J
+TNFα-TNFα
siMTS
Scr
0
500
1000
1500
VEGF-A
TNF
-
- - - -
--+
+ +
+-
Scr siMTS
* *
C
um
. s
pr
ou
t
le
ng
th
 [µ
m
]
FE
JARID1B-ChIP
0.0
0.5
1.0
1.5 ScrsiJ1B-1
ßAct+10 -352 -684
P:MANTIS
*
%
 in
pu
t r
ec
ov
er
y
K
H3K4me3-ChIP
0
1
2
3
4 Scr
siJ1B-1
*
ßAct+10 -352 -684
P:MANTIS
%
 in
pu
t r
ec
ov
er
y
L
0
1
2
3
Scr GFPJ1A J1B J1CshRNA
*
Re
l. 
RN
A
 le
ve
l
MANTIS
M
siMTS
Scr
103 ± 14
203 ± 15
0.0
0.5
1.0
1.5
MTS
gRNA
CTL
*Re
l. 
RN
A
 le
ve
l
MANTIS D MANTIS
0.0
0.5
1.0
1.5
Scr 1 2 3
siRNA
*
*
*
Re
l. 
RN
A
 le
ve
l
B
0.0
0.5
1.0
1.5
2.0
2.5
J1BCTL
*
siRNA
Re
l. 
RN
A
 le
ve
l
0.0
0.5
1.0
1.5
J1BCTL
*
siRNA
MANTIS JARID1BA
MTS
ß-Actin
C
1 2 3 1 2 3
w/o
gRNA
MTS 
gRNA
Supplemental Figure 2: (A) SiRNA knockdown with siScr (CTL) and siJARID1B‐1 in pulmonary artery endothelial cells (PAEC) and qRT‐PCR of MANTIS and
JARID1B. n=6, paired t‐test. (B) MANTIS was measured after targeting with CRISPR/Cas9 gRNAs relative to control (CTL) with qRT‐PCR. n=9, unpaired t‐test. (C)
Agarose gel after PCR of ß‐actin or MANTIS from RNA of HUVECs targeted either with MANTIS gRNAs or empty vector (w/o gRNAs). (D) MANTIS knockdown was
performed with three different siRNAs for 48h and MANTIS expression was measured with qRT‐PCR. Scr served as negative control. n=6. One‐Way ANOVA,
Bonferroni. (E) Spheroid outgrowth assay after MANTIS siRNA‐based knockdown (siMTS). Scrambled siRNA (Scr) served as negative control. Cells treated with or
without TNFα (+/‐ TNFα) (10ng/mL; 16h) are shown. Scale bar indicates 50µm. (F) Quantification of the cumulative sprout length from the spheroid outgrowth
assays seen in Figure 1K and Supplemental Figure 2E. n=10. One‐Way ANOVA, Bonferroni. (G) Tube formation assay after scrambled (Scr) or MANTIS knockdown
(siMTS) in pulmonary artery endothelial cells (PAEC). Scr served as negative control. Numbers indicate number of tubes +/‐ SEM. n=4. Scale bar indicates 200µm.
(H) Boyden‐Chamber assay of HUVECs transfected with siRNAs against scrambled (CTL) or MANTIS (MTS) and calculation of the number of cells migrated into
the lower compartment. n=3, Unpaired t‐test. (I) Competition‐like spheroid outgrowth assay. HUVECs were transfected with lentivirus for CFP or YFP. CFP
transfected cells were transfected with CTL siRNA, whereas YFP transfected cells were transfected with siRNAs against MANTIS (siMTS). Afterwards, cells were
mixed and spheroid outgrowth assay was performed with or without VEGF‐A treatment. Representative images were shown. Scale bar indicates 20µm. (J)
Quantification of tip cells of the spheroid assay shown in Supplemental Figure 2I. n=15, unpaired t‐test. (K, L) ChIP of HUVECs for JARID1B‐ (K) or H3K4me3‐
binding (L) treated with siRNAs against Scrambled (Scr) or JARID1B (siJ1B‐1) followed by qPCR for different regions of theMANTIS (n342419) promoter. Numbers
indicate nucleotide position relative the TSS (+10, ‐352, ‐684). The ßACTIN promoter served as negative control. n=3. Unpaired t‐test. (M) HUVECs were treated
with shRNAs against scrambled (Scr), GFP, JARID1A (J1A), JARID1B (J1B) or JARID1C (J1C) and MANTIS RNA levels were measured by qRT‐PCR relative to ßACTIN.
n=4, unpaired t‐test. Error bars are defined as mean +/‐ SEM. *P<0.05.
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Supplemental Figure 3: (A) QRT‐PCR measurements relative to ß‐Actin after LNA‐GapmeR based knockdown for 48h of MANTIS lncRNA (MTS). CTL served as
negative control and was set to 1. Expression levels of PRCP, TUFT1, IL6, SOX7, HEY1, PECAM1 and RNMT1 are shown. n=6. Paired t‐test. (B) QRT‐PCR
measurements relative to ß‐Actin after knockdown for 48h of MANTIS lncRNA (MTS) with siRNA‐1. Scrambled siRNA (Scr) and MANTIS siRNA‐specific control
siRNA (CTL) served as negative controls. Expression levels of PRCP, TUFT1, IL6, SOX7, HEY1, PECAM1 and RNMT1 are shown. Scr was set to 1 (dashed line). n=7,
except TUFT1 and RNMT1 (n=6). One‐way ANOVA, Bonferroni. (C‐F) SOX18 (C), SMAD6 (D), COUP‐TFII (E) and SOD2 (F) levels were measured after CRISPR/Cas9
mediated knockout of MANTIS (MTS gRNA) with qRT‐PCR relative to ß‐ACTIN. n=9, unpaired t‐test. (G‐L) qRT‐PCR relative to ß‐ACTIN for MANTIS, SOX18,
SMAD6 and COUP‐TFII after siRNA knockdown with scrambled (CTL siRNA) or MANTIS siRNA (siMTS) in carotid artery smooth muscle cells (G, CTASMC, n=7),
coronary artery smooth muscle cells (H, CASMC, n=7), human aortic smooth muscle cells (I, HAoSMC, n=6), human aortic endothelial cells (J, HAoEC, n=7),
human dermal lymphatic endothelial cells (K, HDLEC, n=7) and pulmonary artery endothelial cells (L, PAEC, n=6). CTL was set to 1 (dashed line). Paired t‐test.
(M‐O) QRT‐PCR of SOX18 (M), SMAD6 (N) and COUP‐TFII (O) from endothelial cells isolated from glioblastoma (GBM) or adjacent healthy control (CTL) tissue.
n=5. Paired t‐test. Error bars are defined as mean +/‐ SEM. *P<0.05.
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Supplemental Figure 4: (A) Spheroid outgrowth assay of HUVECs transfected with scrambled (Scr) or MANTIS siRNA‐1 (siMTS) for 48h and with overexpression
of MANTIS, COUP‐TFII, SOX18 or SMAD6 for 24h prior to stopping the assay. PcDNA3.1 (CTL) served as negative control. Cells treated with or without VEGF‐A (+/‐
VEGF‐A) are shown. Scale bar indicates 50µm. (B) HUVECs were transiently transfected with overexpression plasmids (OE) for 48h coding for MANTIS, SMAD6,
COUP‐TFII or SOX18 with subsequent qRT‐PCR measurements. Expression levels of MANTIS (MTS), SMAD6, COUP‐TFII and SOX18 relative to ß‐ACTIN are shown.
PcDNA 3.1 (CTL) served as negative control and was set to 1. n=6. Paired t‐test. (C, D) Quantification of sprout numbers (C) and cumulative sprout length (D)
from the spheroid outgrowth assays seen in Supplemental Figure 4A. n=5. One‐Way ANOVA, Bonferroni. Error bars are defined as mean +/‐ SEM. *P<0.05.
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Supplemental Figure 5: (A) Scatter plot of ATAC‐Seq after knockdown with scrambled siRNA (CTL) or MANTIS siRNA (siMTS) in HUVEC showing log10 normalized
peak counts separated into kernel density smoothing (black) and differential peaks (mean count > 10, log2 fold change > +‐1, red). (B‐D) ChIP of HUVECs
transfected with scrambled (C) or MANTIS siRNA (M) with H3 (B, n=5), H4 (C, n=3) and HP1α (D, n=6) followed by qPCR for GAPDH promoter, Sox18 promoter
regions at the transcription start site (TSS, ‐39nt) or 586nt and 1022nt, SMAD6 promoter regions at the transcription start site (TSS, ‐29nt) or 1491nt and 3031nt,
and COUP‐TFII promoter regions at the transcription start site (TSS, ‐137nt) or 534nt and 3185nt. Numbers indicate nucleotide positions upstream of the TSS.
Unpaired t‐test. Error bars are defined as mean +/‐ SEM. *P<0.05.
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